QUARTERLY REPORT

Q3 2026 — Form 10-Q

Q3 2026PDF · 61 pages356 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the quarterly period ended September 27, 2026
or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from to
Commission file number 1-3215
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey 22-1024240
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of principal executive offices)
Registrant’s telephone number, including area code (732) 524-0400
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. ☑ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, Par Value $1.00 JNJ New York Stock Exchange
1.150% Notes Due November 2028 JNJ28 New York Stock Exchange
2.700% Notes Due February 2029 JNJ29B New York Stock Exchange
3.200% Notes Due June 2032 JNJ32 New York Stock Exchange
3.050% Notes Due February 2033 JNJ33B New York Stock Exchange
1.650% Notes Due May 2035 JNJ35 New York Stock Exchange
3.350% Notes Due June 2036 JNJ36A New York Stock Exchange
3.350% Notes Due February 2037 JNJ37B New York Stock Exchange
3.550% Notes Due June 2044 JNJ44 New York Stock Exchange
3.600% Notes Due February 2045 JNJ45 New York Stock Exchange
3.700% Notes Due February 2055 JNJ55 New York Stock Exchange
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
On October 15, 2026, 2,407,310,266 shares of Common Stock, $1.00 par value, were outstanding.

-- 1 of 61 --

JOHNSON & JOHNSON AND SUBSIDIARIES
Table of contents
Item Page
Part I
Financial information 1
Item 1 Financial statements (unaudited) 1
Consolidated balance sheets — September 27, 2026 and December 28, 2025 1
Consolidated statements of earnings for the fiscal third quarters ended September 27, 2026 and
September 28, 2025 2
Consolidated statements of earnings for the fiscal nine months ended September 27, 2026 and
September 28, 2025 3
Consolidated statements of comprehensive income for the fiscal third quarters and fiscal nine
months ended September 27, 2026 and September 28, 2025 4
Consolidated statements of equity for the fiscal third quarters and fiscal nine months ended
September 27, 2026 and September 28, 2025 5
Consolidated statements of cash flows for the fiscal nine months ended September 27, 2026 and
September 28, 2025 7
Notes to consolidated financial statements 8
Item 2 Management’s discussion and analysis of financial condition and results of operations 37
Item 3 Quantitative and qualitative disclosures about market risk 52
Item 4 Controls and procedures 53
Part II
Other information 54
Item 1 Legal proceedings 54
Item 2 Unregistered sales of equity securities and use of proceeds 54
Item 5 Other information 55
Item 6 Exhibits 55
Signatures 56

-- 2 of 61 --

Cautionary note regarding forward-looking statements
This Quarterly Report on Form 10-Q and Johnson & Johnson’s other publicly available documents contain “forward-looking
statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of
1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make
forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect
management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be
identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and other words of similar meaning in
conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact
of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other
benefits; the Company’s strategy for growth; product development activities; regulatory approvals; market position and
expenditures.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are
subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company’s control.
Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the
Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its
forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and
uncertainties include, but are not limited to:
Risks related to product development, market success and competition
• Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which
the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing
clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial
success;
• Challenges to the Company’s ability to secure and maintain adequate patent and other intellectual property rights for new and
existing products and technologies in the United States and other important markets;
• The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and
resulting revenue and market share losses;
• Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch
competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark
Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales
for the relevant product sooner than expected;
• Competition in research and development of new and improved products, processes and technologies, which can result in
product and process obsolescence;
• Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for
products and technologies;
• Competition based on cost-effectiveness, product performance, technological advances and patents attained by
competitors; and
• Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could
adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future
royalties.
Risks related to product liability, litigation and regulatory activity
• Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals,
recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international
counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
• The impact, including declining sales and reputational damage, of significant litigation or government action adverse to
the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting
strategies;
• The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent
litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal
proceedings;

-- 3 of 61 --

• Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and
prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from
government business;
• Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result
in significant sanctions;
• Potential changes to applicable laws and regulations affecting United States and international operations, including relating to:
approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement
and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;
• Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant
markets, including requirements to comply with medical device reporting regulations and other requirements such as the
European Union’s Medical Devices Regulation;
• Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may
cause exposures to additional tax liabilities potentially in excess of existing reserves; and
• The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the
Securities and Exchange Commission.
Risks related to the Company’s strategic initiatives, healthcare market trends and the planned separation of the Company's
Orthopaedics Business
• Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among
healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly
becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce
costs and government pressure on companies to voluntarily reduce costs and price increases;
• Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to
economic hardship and budgetary constraints;
• Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as
development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of
any such external arrangements due to competitive pressures;
• The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by
the Company may not be realized or may take longer to realize than expected;
• The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized
or may take longer to realize than expected.
• The Company’s ability to satisfy the necessary conditions to consummate the planned separation of the Company’s
Orthopaedics business on a timely basis or at all;
• The Company’s ability to successfully separate the Company’s Orthopaedics business and realize the anticipated benefits from
the planned separation; and
• The structure of the separation transaction and the future operating and financial performance, market position and business
strategy for each company.
Risks related to economic conditions, financial markets and operating internationally
• The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in
countries in which the Company operates;
• The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such
fluctuations on revenues, expenses and resulting margins;
• Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including
any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw
material prices, supply chains market volatility and the pace of product development;
• The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of
governmental controls and restrictive economic policies, and unstable international governments and legal systems;
• The impact of global public health crises and pandemics;
• Changes to global climate, extreme weather and natural disasters that could affect demand for the Company’s products and
services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the
supply chain, and affect the overall design and integrity of the Company’s products and operations;

-- 4 of 61 --

• The impact of global or economic changes or events, including global tensions and war; and
• The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and
economic disruptions and instability of financial and other markets.
Risks related to supply chain and operations
• Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may
lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products
from the market, and potential regulatory action;
• Interruptions and breaches of the Company’s information technology systems or those of the Company’s vendors, which could
result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;
• Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory
requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
• The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take
longer to realize than expected, including due to any required approvals from applicable regulatory authorities.
Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the
fiscal year ended December 28, 2025, for a description of certain risks that could, among other things, cause the Company’s actual
results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not
possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all
potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be
made from time to time, whether as a result of new information or future events or developments.

-- 5 of 61 --

Part I — Financial information
Item 1 — Financial statements
Johnson & Johnson and subsidiaries consolidated balance sheets
(Unaudited; Dollars in Millions Except Share and Per Share Data)
September 27, 2026 December 28, 2025
Assets
Current assets:
Cash and cash equivalents (Note 4) $16,910 19,709
Marketable securities 318 393
Accounts receivable, trade, less allowances $187 (2025, $183) 18,987 17,178
Inventories (Note 2) 15,377 14,191
Prepaid expenses and other 4,759 4,153
Total current assets 56,351 55,624
Property, plant and equipment at cost 55,472 54,364
Less: accumulated depreciation (31,368) (31,195)
Property, plant and equipment, net 24,104 23,169
Intangible assets, net (Note 3) 46,652 50,403
Goodwill (Note 3) 48,474 48,772
Deferred taxes on income (Note 5) 6,748 6,874
Other assets 15,096 14,368
Total assets $197,425 199,210
Liabilities and shareholders’ equity
Current liabilities:
Loans and notes payable $8,852 8,495
Accounts payable 9,317 11,991
Accrued liabilities 12,255 8,594
Accrued rebates, returns and promotions 18,936 19,124
Accrued compensation and employee related obligations 4,121 4,534
Accrued taxes on income (Note 5) 1,976 1,388
Total current liabilities 55,457 54,126
Long-term debt (Note 4) 35,799 39,438
Deferred taxes on income (Note 5) 4,835 6,791
Employee related obligations (Note 6) 6,559 6,957
Long-term taxes payable (Note 5) 497 486
Other liabilities 12,749 9,868
Total liabilities $115,896 117,666
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares;
issued 3,119,843,000 shares)
$3,120 3,120
Accumulated other comprehensive income (loss) (Note 7) (13,765) (14,930)
Retained earnings and Additional paid-in capital 168,358 168,978
Less: common stock held in treasury, at cost (712,725,000 and 711,904,000 shares) 76,184 75,624
Total shareholders’ equity $81,529 81,544
Total liabilities and shareholders’ equity $197,425 199,210
See Notes to Consolidated Financial Statements
Table of Contents
Form 10-Q 1

-- 6 of 61 --

Johnson & Johnson and subsidiaries consolidated statements of
earnings
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
Fiscal Third Quarter Ended
September 27,
2026
Percent
to Sales
September 28,
2025
Percent
to Sales
Sales to customers (Note 9) $25,399 100.0% $23,993 100.0%
Cost of products sold 8,097 31.9 7,303 30.4
Gross profit 17,302 68.1 16,690 69.6
Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7
Research and development expense 4,652 18.3 3,672 15.3
In-process research and development impairments 339 1.4 — —
Interest income (186) (0.7) (227) (0.9)
Interest expense, net of portion capitalized 217 0.8 245 1.0
Other (income) expense, net 5,780 22.8 (478) (2.0)
Restructuring (Note 12) 181 0.7 63 0.3
Earnings before provision for taxes on income 34 0.1 7,493 31.2
(Benefit from)/Provision for taxes on income (Note 5) (176) (0.7) 2,341 9.7
Net earnings $210 0.8 % $5,152 21.5 %
Net earnings per share (Note 8)
Basic $0.09 $2.14
Diluted $0.09 $2.12
Avg. shares outstanding
Basic 2,409.6 2,408.3
Diluted 2,448.6 2,428.6
See Notes to Consolidated Financial Statements
Table of Contents
2

-- 7 of 61 --

Johnson & Johnson and subsidiaries consolidated statements of
earnings
(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)
Fiscal Nine Months Ended
September 27,
2026
Percent
to Sales
September 28,
2025
Percent
to Sales
Sales to customers (Note 9) $74,771 100.0 % $69,629 100.0 %
Cost of products sold 24,254 32.4 22,288 32.0
Gross profit 50,517 67.6 47,341 68.0
Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3
Research and development expense 11,832 15.8 10,413 15.0
In-process research and development impairments 375 0.5 — —
Interest income (634) (0.8) (819) (1.2)
Interest expense, net of portion capitalized 770 1.0 757 1.1
Other (income) expense, net 6,405 8.6 (7,692) (11.1)
Restructuring (Note 12) 247 0.3 144 0.2
Earnings before provision for taxes on income 12,771 17.1 27,615 39.7
Provision for taxes on income (Note 5) 1,792 2.4 5,927 8.6
Net earnings $10,979 14.7 % $21,688 31.1 %
Net earnings per share (Note 8)
Basic $4.56 $9.01
Diluted $4.49 $8.94
Avg. shares outstanding
Basic 2,408.1 2,407.3
Diluted 2,445.8 2,424.8
See Notes to Consolidated Financial Statements
Table of Contents
Form 10-Q 3

-- 8 of 61 --

Johnson & Johnson and subsidiaries consolidated statements of
comprehensive income
(Unaudited; Dollars in Millions)
Fiscal Third Quarter Ended Fiscal Nine Months Ended
September 27,
2026
September 28,
2025
September 27,
2026
September 28,
2025
Net earnings $210 5,152 $10,979 21,688
Other comprehensive income (loss), net of tax
Foreign currency translation 479 (1,292) 2,017 (5,031)
Securities:
Unrealized holding gain (loss) arising during period — — — (1)
Net change — — — (1)
Employee benefit plans:
Prior service cost amortization during period (36) (35) (106) (106)
Gain amortization during period 77 82 229 238
Net change 41 47 123 132
Derivatives & hedges:
Unrealized gain (loss) arising during period (58) 434 (274) 1,642
Reclassifications to earnings (276) (121) (701) (238)
Net change (334) 313 (975) 1,404
Other comprehensive income (loss) 186 (932) 1,165 (3,496)
Comprehensive income $396 4,220 $12,144 18,192
See Notes to Consolidated Financial Statements
The tax cost/(benefit) effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2026 and
2025, respectively: Foreign Currency Translation: $(162) million and $1.1 billion; Employee Benefit Plans: $8 million and $8 million;
Derivatives & Hedges: $(89) million and $83 million.
The tax cost/(benefit) effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2026 and
2025, respectively: Foreign Currency Translation: $(885) million and $2.3 billion; Employee Benefit Plans: $24 million and $29
million; Derivatives & Hedges: $(259) million and $373 million.
Table of Contents
4

-- 9 of 61 --

Johnson & Johnson and subsidiaries consolidated statements of equity
(Unaudited; Dollars in Millions)
Fiscal Third Quarter Ended September 27, 2026
Total
Retained
Earnings and
Additional
Paid-in Capital
Accumulated
Other
Comprehensive
Income (AOCI)
Common
Stock
Issued
Amount
Treasury
Stock
Amount
Balance, June 28, 2026 $84,971 171,665 (13,951) 3,120 (75,863)
Net earnings 210 210 — — —
Cash dividends paid ($1.34 per share) (3,227) (3,227) — — —
Employee compensation and stock option plans 1,101 (290) — — 1,391
Repurchase of common stock (including excise tax) (1,712) — — — (1,712)
Other comprehensive income (loss), net of tax 186 — 186 — —
Balance, September 27, 2026 $81,529 168,358 (13,765) 3,120 (76,184)
Fiscal Nine Months Ended September 27, 2026
Total
Retained
Earnings and
Additional Paid-
in Capital
Accumulated
Other
Comprehensive
Income (AOCI)
Common
Stock
Issued
Amount
Treasury
Stock
Amount
Balance, December 28, 2025 $81,544 168,978 (14,930) 3,120 (75,624)
Net earnings 10,979 10,979 — — —
Cash dividends paid ($3.98 per share) (9,585) (9,585) — — —
Employee compensation and stock option plans 3,391 (2,014) — — 5,405
Repurchase of common stock (including excise tax) (5,965) — — — (5,965)
Other comprehensive income (loss), net of tax 1,165 — 1,165 — —
Balance, September 27, 2026 $81,529 168,358 (13,765) 3,120 (76,184)
Table of Contents
Form 10-Q 5

-- 10 of 61 --

Fiscal Third Quarter Ended September 28, 2025
Total
Retained
Earnings and
Additional
Paid-in Capital
Accumulated
Other
Comprehensive
Income
Common
Stock
Issued
Amount
Treasury
Stock
Amount
Balance, June 29, 2025 $78,473 165,371 (14,305) 3,120 (75,713)
Net earnings 5,152 5,152 — — —
Cash dividends paid ($1.30 per share) (3,132) (3,132) — — —
Employee compensation and stock option plans 1,620 (110) — — 1,730
Repurchase of common stock (including excise tax) (1,904) — — — (1,904)
Other comprehensive income (loss), net of tax (932) — (932) — —
Balance, September 28, 2025 $79,277 167,281 (15,237) 3,120 (75,887)
Fiscal Nine Months Ended September 28, 2025
Total
Retained
Earnings and
Additional Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Common
Stock
Issued
Amount
Treasury
Stock
Amount
Balance, December 29, 2024 $71,490 155,791 (11,741) 3,120 (75,680)
Net earnings 21,688 21,688 — — —
Cash dividends paid ($3.84 per share) (9,250) (9,250) — — —
Employee compensation and stock option plans 2,876 (948) — — 3,824
Repurchase of common stock (4,031) — — — (4,031)
Other comprehensive income (loss), net of tax (3,496) — (3,496) — —
Balance, September 28, 2025 $79,277 167,281 (15,237) 3,120 (75,887)
See Notes to Consolidated Financial Statements
Table of Contents
6

-- 11 of 61 --

Johnson & Johnson and subsidiaries consolidated statements of
cash flows
(Unaudited; Dollars in Millions)
Cash flows from operating activities
Net earnings $10,979 21,688
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles 6,080 5,492
Stock based compensation 1,115 1,045
Asset write-downs 801 123
Charges for acquired in-process research and development assets 964 109
Net gain on sale of assets/businesses (27) (131)
Deferred tax provision (2,110) 5,215
Credit losses and accounts receivable allowances 5 (6)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable (1,759) (2,172)
Increase in inventories (1,152) (1,404)
Increase in accounts payable and accrued liabilities 1,449 1,111
Decrease/(Increase) in other current and non-current assets 1,421 (7,653)
Increase/(Decrease) in other current and non-current liabilities 1,084 (6,196)
Net cash flows from operating activities 18,850 17,221
Cash flows used for investing activities
Additions to property, plant and equipment (3,732) (2,995)
Proceeds from the disposal of assets/businesses, net (Note 10) 88 408
Acquisitions, net of cash acquired (Note 10) (352) (14,459)
Acquired in-process research and development assets / related milestones (Note 10) (995) (385)
Purchases of investments (1,218) (677)
Sales of investments 676 1,442
Credit support agreements activity, net 873 (2,338)
Other (including capitalized licenses and milestones) (199) (99)
Net cash used for investing activities (4,859) (19,103)
Cash flows used for financing activities
Dividends to shareholders (9,585) (9,250)
Repurchase of common stock (5,958) (4,029)
Proceeds from short-term debt, net 15,422 10,673
Repayment of short-term debt, net (16,310) (10,524)
Proceeds from long-term debt, net of issuance costs — 9,138
Repayment of long-term debt (2,004) (1,755)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 2,274 1,831
Credit support agreements activity, net (32) (246)
Other (587) (8)
Net cash used for financing activities (16,780) (4,170)
Effect of exchange rate changes on cash and cash equivalents (10) 178
Decrease in cash and cash equivalents (2,799) (5,874)
Cash and cash equivalents, beginning of period 19,709 24,105
Cash and cash equivalents, end of period 16,910 18,231
Fiscal Nine Months Ended
September 27,
2026
September 28,
2025
See Notes to Consolidated Financial Statements
Table of Contents
Form 10-Q 7

-- 12 of 61 --

Notes to consolidated financial statements
Note 1 — The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction
with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as
contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2025. The unaudited interim
financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the
judgment of management for a fair statement of the results for the periods presented.
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Recently Adopted Accounting Standards
ASU 2025-07: Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)
Effective beginning fiscal year 2026, the Company prospectively adopted the amended guidance issued by the FASB that adds a
scope exception to exclude from derivative accounting non-exchange-traded contracts with variables (underlyings) that are based
on operations or activities specific to one of the parties to the contract. The adoption of this new accounting standard did not have
a material impact on the Company’s consolidated financial statements.
Recently Issued Accounting Standards Not Yet Adopted
There were no new material accounting standards issued in the fiscal nine months of 2026.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled
suppliers with the ability to finance payment obligations from the Company with the third-party financial institutions. The Company
is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its
suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by
a participating supplier’s decision to join in the program.
Confirmed obligations under the program as of September 27, 2026, and December 28, 2025, were $0.8 billion and $0.8 billion,
respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.
Note 2 — Inventories
(Dollars in Millions) September 27, 2026 December 28, 2025
Raw materials and supplies $2,483 2,530
Goods in process 3,930 3,828
Finished goods 8,964 7,833
Total inventories $15,377 14,191
Table of Contents
8

-- 13 of 61 --

Note 3 — Intangible assets and goodwill
Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment
assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2025. Future impairment
tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if
warranted.
(Dollars in Millions) September 27, 2026 December 28, 2025
Intangible assets with definite lives:
Patents and trademarks — gross $60,575 59,156
Less accumulated amortization (34,676) (32,507)
Patents and trademarks — net $25,899 26,649
Customer relationships and other intangibles — gross 21,153 21,361
Less accumulated amortization (15,465) (14,998)
Customer relationships and other intangibles — net(1) $5,688 6,363
Intangible assets with indefinite lives:
Trademarks 1,726 1,772
Purchased in-process research and development 13,339 15,619
Total intangible assets — net $46,652 50,403
(1) The majority is comprised of customer relationships
Goodwill as of September 27, 2026 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine MedTech Total
Goodwill at December 28, 2025 $14,967 33,805 48,772
Goodwill, related to acquisitions — 20 20
Currency translation/Other (219) (99) (318)
Goodwill at September 27, 2026 $14,748 33,726 48,474
The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average
amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of
amortizable intangible assets included in the cost of products sold was $1.2 billion and $1.0 billion for the fiscal third quarters ended
September 27, 2026 and September 28, 2025, respectively. The amortization expense of amortizable intangible assets included in
the cost of products sold was $3.7 billion and $3.4 billion for the fiscal nine months ended September 27, 2026 and September 28,
2025, respectively.
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
2026 2027 2028 2029 2030
$5,100 4,400 3,700 3,600 3,500
See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
Table of Contents
Form 10-Q 9

-- 14 of 61 --

Note 4 — Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to
the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign
currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both
types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.
These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign
exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to
offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated
as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current
earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk
related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties
establishing collateral thresholds based on respective credit ratings and netting agreements. As of September 27, 2026, the
cumulative amount of cash collateral paid by the Company under the CSA amounted to $3.8 billion net, related to net investment
and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-
performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least
an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in
this footnote for receivables and payables with these commercial institutions. As of September 27, 2026, the Company had
notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps
of $44.3 billion, $34.0 billion and $7.0 billion, respectively. As of December 28, 2025, the Company had notional amounts
outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $40.6 billion,
$38.9 billion and $8.0 billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each
period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge
transaction, and if so, the type of hedge transaction.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are
expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward
method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item
impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the
underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest
rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted
for through the currency translation account within accumulated other comprehensive income. The portion excluded from
effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company
assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is
no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the
Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce
the volatility caused by changes in exchange rates.
As of September 27, 2026, the balance of deferred net loss on derivatives included in accumulated other comprehensive income
was $1.3 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The
Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into
earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of
time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment
hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses
are ultimately determined by actual exchange rates at maturity of the derivative.
Table of Contents
10

-- 15 of 61 --

The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended
September 27, 2026 and September 28, 2025, net of tax:
September 27, 2026 September 28, 2025
(Dollars in Millions) Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net
investment and cash flow
hedging:
Gain (Loss) on fair value
hedging relationship:
Interest rate swaps
contracts:
Hedged items $— — — (38) — — — — 130 —
Derivatives designated as
hedging instruments
— — — 38 — — — — (130) —
Gain (Loss) on net
investment hedging
relationship:
Cross currency interest rate
swaps contracts:
Amount of gain or (loss)
recognized in income on
derivative amount excluded
from effectiveness testing
— — — 40 — — — — 47 —
Amount of gain or (loss)
recognized in AOCI
— — — 40 — — — — 47 —
Gain (Loss) on cash flow
hedging relationship:
Forward foreign exchange
contracts:
Amount of gain or (loss)
reclassified from AOCI into
income
(2) 128 9 — 6 1 19 (21) — (10)
Amount of gain or (loss)
recognized in AOCI
1 (130) (3) — (2) (6) 100 2 — —
Cross currency interest rate
swaps contracts:
Amount of gain or (loss)
reclassified from AOCI into
income
— — — 94 — — — — 85 —
Amount of gain or (loss)
recognized in AOCI
$— — — 36 — — — — 291 —
Table of Contents
Form 10-Q 11

-- 16 of 61 --

The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended
September 27, 2026 and September 28, 2025, net of tax:
September 27, 2026 September 28, 2025
(Dollars in Millions) Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net
investment and cash flow
hedging:
Gain (Loss) on fair value
hedging relationship:
Interest rate swaps contracts:
Hedged items $— — — (33) — — — — 370 —
Derivatives designated as
hedging instruments
— — — 33 — — — — (370) —
Gain (Loss) on net investment
hedging relationship:
Cross currency interest rate
swaps contracts:
Amount of gain or (loss)
recognized in income on
derivative amount excluded
from effectiveness testing
— — — 132 — — — — 145 —
Amount of gain or (loss)
recognized in AOCI
— — — 132 — — — — 145 —
Gain (Loss) on cash flow
hedging relationship:
Forward foreign exchange
contracts:
Amount of gain or (loss)
reclassified from AOCI into
income
(3) 291 14 — 7 2 (103) (36) — (13)
Amount of gain or (loss)
recognized in AOCI
(11) (515) 74 — 41 8 671 (106) — (40)
Cross currency interest rate
swaps contracts:
Amount of gain or (loss)
reclassified from AOCI into
income
— — — 259 — — — — 243 —
Amount of gain or (loss)
recognized in AOCI
$— — — 5 — — — — 964 —
Table of Contents
12

-- 17 of 61 --

As of September 27, 2026, and December 28, 2025, the following amounts were recorded on the Consolidated Balance Sheet
related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet
in which the hedged item is included
Carrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions) September 27, 2026 December 28, 2025 September 27, 2026 December 28, 2025
Long-term Debt $7,278 8,318 (738) (694)
The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters ended 2026
and 2025:
Gain/(Loss)
Recognized In
Income on Derivative
Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)
Location of
Gain /(Loss)
Recognized in
Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended
Derivatives Not Designated as Hedging Instruments
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Foreign Exchange Contracts
Other (income)
expense $14 33 (85) 76
The following table is the effect of net investment hedges for the fiscal third quarters ended in 2026 and 2025:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated
OCI Into Income
Gain/(Loss)
Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Debt $(16) — Interest (income) expense — —
Cross Currency interest rate swaps $54 123 Interest (income) expense — —
The following table is the effect of net investment hedges for the fiscal nine months ended in 2026 and 2025:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated
OCI Into Income
Gain/(Loss)
Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions) September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Debt $361 (1,119) Interest (income) expense — —
Cross Currency interest rate swaps $399 264 Interest (income) expense — —
Table of Contents
Form 10-Q 13

-- 18 of 61 --

The Company holds equity investments with readily determinable fair values and equity investments without readily determinable
fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus
impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a
similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
December 28, 2025 September 27, 2026
(Dollars in Millions) Carrying Value
Changes in Fair
Value Reflected in
Net Income (1)
(Sales)/
Purchases/
Other (2) Carrying Value
Non Current
Other Assets
Equity Investments with readily
determinable value $665 211 (52) 824 824
Equity Investments without readily
determinable value $910 (130) 545 1,325 1,325
(1) Recorded in Other (income)/expense, net. Equity Investments without readily determinable value includes the option premium related to Sail
Biomedicines (Sail).
(2) Equity Investments without readily determinable value includes equity investment in Sail. Other includes impact of currency
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based
measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with
ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy
are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the
aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and
subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values
of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the
changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The
Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The
Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified
as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the
determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
Table of Contents
14

-- 19 of 61 --

The Company’s significant financial assets and liabilities measured at fair value as of September 27, 2026 and December 28, 2025
were as follows:
September 27, 2026 December 28, 2025
(Dollars in Millions) Level 1 Level 2 Level 3 Total Total(1)
Derivatives designated as hedging instruments:
Assets:
Forward foreign exchange contracts $— 541 — 541 686
Interest rate contracts(2) — 627 — 627 589
Total — 1,168 — 1,168 1,275
Liabilities:
Forward foreign exchange contracts — 639 — 639 413
Interest rate contracts(2) — 4,121 — 4,121 5,848
Total — 4,760 — 4,760 6,261
Derivatives not designated as hedging instruments:
Assets:
Forward foreign exchange contracts — 71 — 71 38
Liabilities:
Forward foreign exchange contracts — 83 — 83 46
Other Investments:
Equity investments(3) 824 — — 824 665
Debt securities(4) — 3,456 — 3,456 2,854
Other Liabilities:
Contingent consideration(5) $— — 729 729 753
Gross to Net Derivative Reconciliation September 27, 2026 December 28, 2025
(Dollars in Millions)
Total Gross Assets $1,239 1,313
Credit Support Agreement (CSA) (1,066) (1,308)
Total Net Asset 173 5
Total Gross Liabilities 4,843 6,307
Credit Support Agreement (CSA) (4,821) (5,903)
Total Net Liabilities $22 404
Summarized information about changes in liabilities for contingent consideration for the fiscal third quarters ended September 27,
2026 and September 28, 2025 is as follows:
September 27, 2026 September 28, 2025
(Dollars in Millions)
Beginning Balance $753 1,217
Changes in estimated fair value(6) (94) (57)
Additions 70 —
Payments — (50)
Ending Balance $729 1,110
(1) 2025 assets and liabilities are all classified as Level 2 with the exception of equity investments of $665 million, which are classified as Level 1
and contingent consideration of $753 million, classified as Level 3.
(2) Includes cross currency interest rate swaps and interest rate swaps.
(3) Classified as non-current other assets.
Table of Contents
Form 10-Q 15

-- 20 of 61 --

(4) Classified within cash equivalents and current marketable securities.
(5) Classified as non-current other liabilities.
(6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense or Other (income) expense, net.
As of September 27, 2026, and December 28, 2025, cash and cash equivalents include money market funds of $4,936 million and $5,993 million,
respectively, which would be considered level 1 in the fair value hierarchy.
The Company's cash, cash equivalents and current marketable securities as of September 27, 2026 comprised:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash $3,276 3,276 3,276 —
Non-U.S. sovereign securities 7 7 — 7
U.S. reverse repurchase agreements 4,774 4,774 4,774 —
Money market funds 4,936 4,936 4,936 —
Time deposits(1) 779 779 779 —
Subtotal 13,772 13,772 13,765 7
U.S. Gov’t securities 2,995 2,995 2,983 12
Other sovereign securities 224 224 117 107
Corporate and other debt securities 237 237 45 192
Subtotal available for sale debt(2) $3,456 3,456 3,145 311
Total cash, cash equivalents and current
marketable securities $17,228 17,228 16,910 318
(1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive
income.
As of the fiscal year ended December 28, 2025, the carrying amount of cash, cash equivalents and current marketable securities
was the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and
significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash
equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as
current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of
purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of September 27, 2026 are as follows:
(Dollars in Millions) Cost Basis Fair Value
Due within one year $3,452 3,452
Due after one year through five years 4 4
Due after five years through ten years — —
Total debt securities $3,456 3,456
Table of Contents
16

-- 21 of 61 --

Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 27, 2026:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities
Loans and Notes Payable $8,852 8,800
Non-Current Debt
2.90% Notes due 2028 1,499 1,465
1.150% Notes due 2028 (750MM Euro 1.1372) 851 812
4.55% Notes due 2028 749 748
4.80% Notes due 2029 1,147 1,144
6.95% Notes due 2029 299 317
2.70% Notes due 2029 (600MM Euro 1.1372) 682 669
1.30% Notes due 2030 1,710 1,516
4.70% Notes due 2030 997 988
4.90% Notes due 2031 1,147 1,138
3.20% Notes due 2032 (700MM Euro 1.1372) 794 767
4.85% Notes due 2032 1,244 1,230
4.95% Notes due 2033 499 494
4.375% Notes due 2033 853 807
3.050% Notes due 2033 (700MM Euro 1.1372) 794 754
4.95% Notes due 2034 847 833
1.650% Notes due 2035 (1.5B Euro 1.1372) 1,697 1,396
5.00% Notes due 2035 1,244 1,218
3.35% Notes due 2036 (800MM Euro 1.1372) 905 849
3.587% Notes due 2036 920 856
5.95% Notes due 2037 995 1,039
3.625% Notes due 2037 1,404 1,280
3.350% Notes due 2037 (1.0B Euro 1.1372) 1,135 1,048
3.40% Notes due 2038 994 817
5.85% Notes due 2038 697 717
4.50% Notes due 2040 542 488
2.10% Notes due 2040 886 654
4.85% Notes due 2041 298 273
4.50% Notes due 2043 497 431
3.55% Notes due 2044 (1.0B Euro 1.1372) 1,128 1,000
3.60% Notes due 2045 (700MM Euro 1.1372) 791 700
3.73% Notes due 2046 1,980 1,473
3.75% Notes due 2047 857 734
3.50% Notes due 2048 744 521
2.25% Notes due 2050 833 529
5.25% Notes due 2054 844 775
3.70% Notes due 2055 (1.0B Euro 1.1372) 1,131 964
2.45% Notes due 2060 1,087 613
Other 78 81
Total Long Term Debt $35,799 32,138
Table of Contents
Form 10-Q 17

-- 22 of 61 --

The weighted average effective interest rate on non-current debt is 3.68%.
The excess of the carrying value over the estimated fair value of debt was $1.7 billion at December 28, 2025.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and
significant other observable inputs.
The current debt balance as of September 27, 2026, includes $5.6 billion of commercial paper which has a weighted average
interest rate of 3.76% and a weighted average maturity of approximately two months. The current debt balance as of December
28, 2025, included $6.5 billion of commercial paper which had a weighted average interest rate of 3.81% and a weighted average
maturity of approximately two months.
Note 5 — Income taxes
The worldwide effective income tax rates for the fiscal nine months of 2026 and 2025 were 14.0% and 21.5%, respectively. The
primary drivers for year over year change in the Company’s effective tax were:
• In the fiscal third quarter of 2026, the Company recorded a $5.5 billion accrual related to the proposed resolution of talc ovarian
litigation which reduced the 2026 year to date effective tax rate by approximately 2.5% versus an accrual reversal of
approximately $7.0 billion related to the talc reserve in the fiscal first quarter of 2025 which increased the 2025 effective tax
rate by approximately 0.3%.
• In the fiscal third quarter of 2025, the United States enacted the One Big Beautiful Bill Act (OBBBA). The OBBBA included
provisions modifying the corporate income tax code, including the immediate expensing of domestic research and development
expenditures for tax purposes, 100% bonus depreciation for qualified assets, and an increase in the statutory tax rate on foreign
earnings from 10.5% to 12.6%. As a result, the Company remeasured its deferred tax balances for the changes in the tax rate and
recorded a one-time remeasurement cost of approximately $1.0 billion which increased the 2025 effective tax rate by
approximately 3.6%.
• Additional tax benefits in the fiscal first nine months of 2026 and 2025 related to the Company’s share-based equity
compensation programs that either vested or were exercised during the fiscal nine months of 2026 and 2025, which reduced the
effective tax rate by 3.7% and 0.4%, respectively.
As of September 27, 2026, the Company had approximately $2.8 billion of liabilities from unrecognized tax benefits. The Company
conducts business and files tax returns in numerous countries and currently has tax audits in progress in several jurisdictions. With
respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and the audit for
tax years 2017 through 2020 is ongoing. In other major jurisdictions where the Company conducts business, the years that remain
open to tax audit go back to the year 2014.
Table of Contents
18

-- 23 of 61 --

Note 6 — Pensions and other benefit plans
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the
following components:
Fiscal Third Quarter Ended Fiscal Nine Months Ended
Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans
(Dollars in Millions) September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Service cost $235 223 81 72 706 656 241 216
Interest cost 359 358 52 54 1,079 1,065 156 161
Expected return on plan
assets (636) (604) (1) (2) (1,913) (1,790) (5) (5)
Amortization of prior
service cost/(credit) (46) (46) — — (138) (138) (1) (1)
Recognized actuarial
(gains)/losses 69 86 26 16 208 254 78 47
Curtailments and
settlements 1 — — 1 1 — —
Net periodic benefit cost/
(credit) $(18) 17 158 140 (57) 48 469 418
The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of
Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development
expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as
part of Other (income) expense, net on the Consolidated Statement of Earnings.
Company contributions
For the fiscal nine months ended September 27, 2026, the Company contributed $94 million and $15 million to its U.S. and
international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with
the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.
Table of Contents
Form 10-Q 19

-- 24 of 61 --

Note 7 — Accumulated other comprehensive income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 28, 2025 $(13,947) — (693) (290) (14,930)
Net change 2,017 — 123 (975) 1,165
September 27, 2026 $(11,930) — (570) (1,265) (13,765)
Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is
not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on
comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying
transaction. See Note 4 for additional details.
Note 8 — Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Shares in Millions)
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Basic net earnings per share $0.09 2.14 4.56 9.01
Average shares outstanding — basic 2,409.6 2,408.3 2,408.1 2,407.3
Potential shares exercisable under stock option plans 95.1 124.3 93.8 89.3
Less: shares which could be repurchased under treasury stock method (56.1) (104.0) (56.1) (71.8)
Average shares outstanding — diluted 2,448.6 2,428.6 2,445.8 2,424.8
Diluted net earnings per share $0.09 2.12 4.49 8.94
(Shares in Millions)
The diluted net earnings per share calculation excluded the following
number of shares related to stock options, as the exercise price of
these options was greater than the average market value of the
Company’s stock. 0.0 0.0 5.6 38.8
Table of Contents
20

-- 25 of 61 --

Note 9 — Segments of business and geographic areas
The Company is organized into two business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the
Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including
employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM
considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources
to the segments.
Sales by segment of business
INNOVATIVE MEDICINE
Oncology
U.S. $4,267 3,468 23.0 % $11,951 9,866 21.1 %
International 3,335 3,060 9.0 10,030 8,652 15.9
Worldwide 7,602 6,529 16.4 21,981 18,519 18.7
DARZALEX
U.S. 2,528 2,088 21.1 7,171 5,934 20.9
International 1,711 1,584 8.0 5,239 4,514 16.1
Worldwide 4,239 3,672 15.4 12,410 10,448 18.8
CARVYKTI
U.S. 472 396 19.4 1,377 1,072 28.5
International 238 128 85.3 587 260 *
Worldwide 710 524 35.5 1,964 1,332 47.4
TECVAYLI
U.S. 236 115 * 549 334 64.4
International 77 62 24.0 225 160 40.6
Worldwide 312 177 76.6 774 494 56.7
TALVEY
U.S. 112 85 31.6 325 235 38.1
International 59 37 62.9 172 79 *
Worldwide 171 122 40.9 497 314 58.3
RYBREVANT/ LAZCLUZE
U.S. 201 136 47.9 566 388 46.1
International 119 61 94.5 300 130 *
Worldwide 320 198 62.3 866 518 67.4
ERLEADA
U.S. 423 378 11.8 1,161 1,048 10.8
International 600 558 7.7 1,806 1,567 15.3
Worldwide 1,023 936 9.4 2,967 2,615 13.5
IMBRUVICA
U.S. 145 211 (31.6) 437 685 (36.3)
International 420 483 (13.2) 1,386 1,453 (4.7)
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
Table of Contents
Form 10-Q 21

-- 26 of 61 --

Worldwide 563 695 (18.8) 1,822 2,139 (14.8)
OTHER ONCOLOGY(1)
U.S. 149 61 * 365 171 *
International 111 147 (24.4) 314 488 (35.7)
Worldwide 262 207 26.3 680 659 3.2
Immunology
U.S. 2,804 2,676 4.8 7,031 7,377 (4.7)
International 1,417 1,493 (5.1) 4,414 4,492 (1.7)
Worldwide 4,221 4,168 1.3 11,445 11,868 (3.6)
TREMFYA
U.S. 1,772 989 79.1 4,279 2,384 79.5
International 624 434 43.7 1,771 1,181 49.9
Worldwide 2,396 1,424 68.3 6,050 3,566 69.7
SIMPONI / SIMPONI ARIA
U.S. 269 309 (13.2) 798 906 (11.9)
International 299 377 (20.6) 1,035 1,130 (8.4)
Worldwide 568 687 (17.3) 1,833 2,036 (10.0)
REMICADE
U.S. 258 326 (20.8) 742 923 (19.6)
U.S. Exports 12 19 (37.1) 40 63 (36.6)
International 124 132 (6.2) 372 413 (9.8)
Worldwide 394 476 (17.3) 1,154 1,398 (17.5)
STELARA
U.S. 368 1,022 (64.0) 924 3,081 (70.0)
International 349 549 (36.5) 1,188 1,768 (32.8)
Worldwide 716 1,570 (54.4) 2,112 4,848 (56.4)
OTHER IMMUNOLOGY
U.S. 126 12 * 249 21 *
International 21 0 * 48 0 *
Worldwide 147 12 * 297 21 *
Neuroscience
U.S. 1,733 1,367 26.8 4,886 3,712 31.6
International 642 658 (2.4) 2,001 2,011 (0.5)
Worldwide 2,375 2,024 17.3 6,887 5,722 20.3
SPRAVATO
U.S. 559 405 37.9 1,479 1,047 41.3
International 66 53 22.7 197 146 34.8
Worldwide 624 459 36.1 1,676 1,193 40.5
CAPLYTA(2)
U.S. 398 240 66.1 1,029 451 *
International — — — — — —
Worldwide 398 240 66.1 1,029 451 *
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
Table of Contents
22

-- 27 of 61 --

INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA
U.S. 739 664 11.4 2,235 2,021 10.6
International 258 267 (3.0) 816 804 1.5
Worldwide 998 929 7.3 3,051 2,824 8.0
CONCERTA / methylphenidate
U.S. 6 14 (56.3) 40 76 (47.3)
International 138 127 8.1 386 376 2.4
Worldwide 143 140 2.1 425 452 (5.9)
OTHER NEUROSCIENCE
U.S. 32 46 (30.6) 104 119 (12.6)
International 180 210 (14.3) 602 684 (12.0)
Worldwide 212 256 (17.3) 706 803 (12.1)
Pulmonary Hypertension (PH)
U.S. 588 815 (27.8) 2,233 2,358 (5.3)
International 309 300 2.9 942 895 5.2
Worldwide 897 1,115 (19.5) 3,175 3,253 (2.4)
UPTRAVI
U.S. 383 392 (2.2) 1,154 1,139 1.3
International 100 92 8.9 306 272 12.7
Worldwide 483 484 (0.1) 1,460 1,411 3.5
OPSUMIT/OPSYNVI
U.S. 193 409 (52.8) 1,042 1,175 (11.3)
International 179 168 5.9 538 507 6.0
Worldwide 372 578 (35.7) 1,580 1,682 (6.1)
OTHER PULMONARY HYPERTENSION
U.S. 12 13 (7.3) 37 44 (15.5)
International 30 39 (23.8) 98 116 (15.6)
Worldwide 42 53 (19.7) 135 160 (15.6)
Infectious Diseases (ID)
U.S. 317 326 (2.7) 959 961 (0.2)
International 496 501 (1.2) 1,506 1,472 2.3
Worldwide 813 829 (1.8) 2,465 2,434 1.3
EDURANT / rilpivirine
U.S. 5 7 (31.6) 15 21 (30.1)
International 382 378 1.0 1,131 1,082 4.5
Worldwide 386 385 0.4 1,145 1,103 3.8
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
U.S. 307 315 (2.5) 937 932 0.6
International 74 81 (8.9) 259 264 (1.9)
Worldwide 381 397 (3.8) 1,196 1,196 0.0
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
Table of Contents
Form 10-Q 23

-- 28 of 61 --

OTHER INFECTIOUS DISEASES
U.S. 5 4 29.9 7 8 (11.4)
International 40 42 (6.2) 116 126 (8.0)
Worldwide 46 47 (3.0) 124 135 (8.2)
Cardiovascular / Metabolism / Other (CVM)
U.S. 736 750 (1.9) 2,235 2,381 (6.1)
International 112 149 (24.3) 378 461 (17.9)
Worldwide 849 899 (5.6) 2,614 2,842 (8.0)
XARELTO
U.S. 653 635 2.7 1,959 1,946 0.7
International — — — — — —
Worldwide 653 635 2.7 1,959 1,946 0.7
OTHER
U.S. 84 115 (27.2) 276 435 (36.5)
International 112 149 (24.3) 378 461 (17.9)
Worldwide 197 264 (25.5) 655 896 (26.9)
Total PH, ID, CVM
U.S. 1,643 1,891 (13.2) 5,428 5,700 (4.8)
International 917 950 (3.5) 2,826 2,828 (0.1)
Worldwide 2,560 2,843 (9.9) 8,254 8,529 (3.2)
TOTAL INNOVATIVE MEDICINE
U.S. 10,447 9,402 11.1 29,297 26,655 9.9
International 6,310 6,161 2.4 19,270 17,983 7.2
Worldwide 16,757 15,563 7.7 48,567 44,638 8.8
MEDTECH
Cardiovascular
U.S. 1,397 1,306 7.0 4,222 3,931 7.4
International 910 908 0.2 2,866 2,698 6.2
Worldwide 2,307 2,213 4.3 7,088 6,629 6.9
ELECTROPHYSIOLOGY
U.S. 771 720 7.0 2,290 2,145 6.8
International 717 698 2.8 2,219 2,064 7.5
Worldwide 1,487 1,418 4.9 4,509 4,209 7.1
ABIOMED
U.S. 335 336 (0.3) 1,066 1,035 3.0
International 78 86 (10.4) 275 256 7.2
Worldwide 412 423 (2.3) 1,340 1,291 3.8
SHOCKWAVE
U.S. 261 220 18.8 771 659 17.0
International 64 59 9.3 194 169 14.8
Worldwide 325 278 16.8 965 828 16.6
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
Table of Contents
24

-- 29 of 61 --

OTHER CARDIOVASCULAR
U.S. 31 30 3.6 96 93 3.2
International 50 65 (21.9) 177 209 (15.0)
Worldwide 81 95 (13.9) 273 302 (9.4)
Surgery
U.S. 1,070 1,031 3.7 3,210 3,076 4.3
International 1,459 1,511 (3.4) 4,483 4,417 1.5
Worldwide 2,528 2,542 (0.6) 7,692 7,493 2.7
ADVANCED
U.S. 500 477 5.1 1,476 1,411 4.7
International 654 688 (5.0) 1,991 1,991 0.0
Worldwide 1,155 1,165 (0.9) 3,467 3,402 1.9
GENERAL
U.S. 568 555 2.4 1,733 1,666 4.0
International 805 823 (2.2) 2,492 2,426 2.7
Worldwide 1,373 1,378 (0.3) 4,225 4,092 3.3
Vision
U.S. 596 571 4.3 1,740 1,694 2.7
International 865 828 4.4 2,537 2,354 7.8
Worldwide 1,461 1,400 4.4 4,277 4,048 5.6
CONTACT LENSES / OTHER
U.S. 465 456 1.9 1,378 1,337 3.1
International 588 562 4.7 1,669 1,565 6.6
Worldwide 1,053 1,018 3.5 3,047 2,902 5.0
SURGICAL
U.S. 132 116 13.6 363 358 1.4
International 276 266 3.8 867 789 10.0
Worldwide 408 383 6.8 1,230 1,147 7.3
Orthopaedics
U.S. 1,448 1,396 3.8 4,353 4,200 3.6
International 898 878 2.2 2,794 2,620 6.6
Worldwide 2,345 2,274 3.2 7,146 6,820 4.8
HIPS
U.S. 271 262 3.5 831 796 4.4
International 148 144 2.6 465 440 5.7
Worldwide 419 405 3.1 1,296 1,235 4.9
KNEES
U.S. 221 216 2.1 688 673 2.2
International 165 160 3.0 528 482 9.7
Worldwide 386 377 2.5 1,216 1,155 5.3
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
Table of Contents
Form 10-Q 25

-- 30 of 61 --

TRAUMA
U.S. 555 512 8.6 1,623 1,515 7.1
International 288 281 2.4 880 818 7.6
Worldwide 844 793 6.4 2,504 2,333 7.3
SPINE, SPORTS & OTHER
U.S. 401 406 (1.2) 1,211 1,216 (0.4)
International 296 293 1.3 920 881 4.5
Worldwide 697 698 (0.1) 2,131 2,096 1.7
TOTAL MEDTECH
U.S. 4,512 4,306 4.8 13,525 12,902 4.8
International 4,130 4,124 0.1 12,679 12,089 4.9
Worldwide 8,642 8,430 2.5 26,204 24,991 4.9
WORLDWIDE
U.S. 14,959 13,708 9.1 42,822 39,557 8.3
International 10,440 10,285 1.5 31,949 30,072 6.2
Worldwide $25,399 23,993 5.9% $74,771 69,629 7.4%
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September
27,
2026
September
28,
2025
Percent
Change
September
27,
2026
September
28,
2025
Percent
Change
* Percentage greater than 100% or not meaningful
(1) Includes the sales of ZYTIGA which were previously disclosed separately
(2) Acquired with Intra-Cellular Therapies on April 2, 2025
Adjustments to revenue recognized as a result of changes in estimates for the Company's most significant U.S. rebates and
discounts liability balances for products shipped in previous years were approximately 0.4% and 2.4% of U.S. Innovative Medicine
revenue during the fiscal third quarter of 2026 and 2025, respectively and approximately 2.6% and 3.1% of U.S. Innovative Medicine
revenue during the fiscal nine months of 2026 and 2025, respectively.
In October 2025, the Company announced its intention to separate its Orthopaedics business and expects the separation to be
completed in mid-2027.
Table of Contents
26

-- 31 of 61 --

Segment income before tax
Fiscal Third Quarter Ended
(Dollars in Millions)
September 27,
2026
September 28,
2025
Innovative
Medicine(1) MedTech(2) Total
Innovative
Medicine(1) MedTech(2) Total
Sales to customers $16,757 8,642 15,563 8,430
Cost of products sold 4,486 3,597 3,672 3,612
Selling, marketing and administrative 3,035 3,014 2,869 2,801
Research and development expense 3,888 764 2,944 728
Other segment items (3) 282 491 (368) 2
Segment income before tax $5,066 776 5,842 6,446 1,287 7,733
(Income)/Expense not allocated to segments (4) 5,808 240
Earnings before provision for taxes on income $34 $7,493
Fiscal Nine Months Ended
Sales to customers $48,567 26,204 44,638 24,991
Cost of products sold 13,172 11,035 11,670 10,576
Selling, marketing and administrative 9,083 8,989 7,919 8,319
Research and development expense 9,576 2,256 8,361 2,052
Other segment items (3) 104 732 (520) 132
Segment income before tax $16,632 3,192 19,824 17,208 3,912 21,120
(Income)/Expense not allocated to segments (4) 7,053 (6,495)
Earnings before provision for taxes on income $12,771 $27,615
(1) Innovative Medicine includes:
• Intangible amortization expense of $0.8 billion and $0.6 billion in the fiscal third quarters of 2026 and 2025, respectively.
Intangible amortization expense of $2.3 billion and $2.0 billion in the fiscal nine months of 2026 and 2025, respectively.
• Restructuring related charge of $0.1 billion and $0.3 billion in the fiscal third quarter and fiscal nine months of 2026, respectively. Refer to
Note 12 for additional details.
• Acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly Bio, Inc. in the fiscal
third quarter and fiscal nine months of 2026. Refer to Note 10 for additional details.
• Expense of $0.3 billion related to the strategic collaboration with Sail Biomedicines (Sail) in the fiscal third quarter and fiscal nine months of
2026. Refer to Note 10 for additional details.
(2) MedTech includes:
• Intangible amortization expense of $0.5 billion in both the fiscal third quarters of 2026 and 2025.
Intangible amortization expense of $1.4 billion in both the fiscal nine months of 2026 and 2025.
• Orthopaedics Separation related costs of $0.4 billion and $0.7 billion in the fiscal third quarter and fiscal nine months of 2026, respectively
as compared to $0 in the fiscal third quarter and fiscal nine months of 2025.
• In-process research and development impairment charges of $0.3 billion and $0.4 billion in the fiscal third quarter and fiscal nine months of
2026, respectively, primarily related to PreCardia, a non-strategic asset acquired as part of the Abiomed acquisition in 2022.
• Impact of tariff recoveries of approximately $0.2 billion in the fiscal third quarter and fiscal nine months of 2026.
(3) Other segment items for each reportable segment include other income and expense (gains and losses on divestitures and sales of assets),
restructuring activities and impairment charges related to in-process research and development
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal third quarter and
fiscal nine months of 2026 includes a charge of $5.5 billion related to the proposed talc ovarian litigation resolution. The fiscal nine months of
2025 includes approximately $7.0 billion related to the talc reserve reversal.
Table of Contents
Form 10-Q 27

-- 32 of 61 --

Identifiable Assets
(Dollars in Millions) September 27, 2026 December 28, 2025
Innovative Medicine $78,944 78,057
MedTech 86,214 86,482
Total 165,158 164,539
General corporate (1) 32,267 34,671
Worldwide total $197,425 199,210
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
Fiscal Nine Months Ended
(Dollars in Millions)
September 27,
2026
September 28,
2025
September 27,
2026
September 28,
2025
Innovative Medicine $1,865 1,166 $3,258 2,757
MedTech 1,701 1,674 2,638 2,564
Segments total 3,566 2,840 5,896 5,321
General corporate 166 155 184 171
Worldwide total $3,732 2,995 $6,080 5,492
Sales by geographic area
Fiscal Third Quarter Ended Fiscal Nine Months Ended
(Dollars in Millions)
September 27,
2026
September 28,
2025
Percent
Change
September 27,
2026
September 28,
2025
Percent
Change
United States $14,959 13,708 9.1% $42,822 39,557 8.3%
Europe 5,405 5,440 (0.6) 16,979 15,937 6.5
Western Hemisphere, excluding U.S. 1,385 1,231 12.5 3,987 3,604 10.6
Asia-Pacific, Africa 3,650 3,614 1.0 10,983 10,531 4.3
Total $25,399 23,993 5.9% $74,771 69,629 7.4%
Note 10 — Acquisitions, divestitures and other arrangements
Business combinations
Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this
method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the
Company’s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets,
where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company’s
financial statements from their respective dates of acquisition.
In the fiscal nine months of 2026, there were no material business combinations.
2025 Transactions
During the fiscal year 2025, the Company acquired Halda Therapeutics OpCo, Inc. (Halda Therapeutics) and Intra-Cellular
Therapies, Inc. (Intra-Cellular) for a total of $17.5 billion, net of cash acquired.
Halda Therapeutics
On December 26, 2025, the Company completed the acquisition of Halda Therapeutics, a clinical-stage biotechnology company
with proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeting therapies for
Table of Contents
28

-- 33 of 61 --

multiple types of solid tumors, including prostate cancer, in an all-cash merger transaction for total consideration transferred of
approximately $3.05 billion, net of cash acquired. The acquisition was accounted for as a business combination and the results of
operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. Included in the total
consideration transferred was $0.2 billion of acquisition-related costs, primarily related to post-closing compensation expense due
to the acceleration of equity awards. This expense was recorded in Other (income) expense, net. Acquisition related costs before
tax for the fiscal nine months of 2026 were not material.
The fair value of the assets acquired is $3.4 billion, which primarily relates to acquired in-process research and development
(IPR&D) of $2.8 billion and goodwill of $0.6 billion. The fair value of the liabilities assumed is $0.6 billion, primarily related to
deferred taxes. These values are preliminary and based on the best estimate of management, which is subject to change within the
measurement period. As of the fiscal nine months ended September 27, 2026, there have been no material measurement period
adjustments.
Intra-Cellular
On April 2, 2025, the Company completed the acquisition of Intra-Cellular, a biopharmaceutical company focused on the
development and commercialization of therapeutics for central nervous system disorders. This acquisition advances the Company’s
industry-leading portfolio in mental health with the addition of CAPLYTA (lumateperone), the first and only U.S. FDA-approved
treatment for bipolar I and II depression as an adjunctive therapy and monotherapy and is also approved for the treatment of
schizophrenia in adults. This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized
anxiety disorder and Alzheimer’s disease-related psychosis and agitation.
The Company acquired all the outstanding shares of Intra-Cellular’s common stock for $132.00 per share in an all-cash merger
transaction for total consideration transferred of $14.5 billion. The acquisition was accounted for as a business combination and
the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. In addition,
acquisition-related costs before tax incurred during the fiscal year 2025 were $0.4 billion, of which $0.1 billion related to post-
closing compensation expense due to the acceleration of equity awards and were recorded to Other (income) expense, net.
Acquisition related costs before tax for the fiscal nine months of 2026 were not material.
The fair value of the assets acquired is $17.5 billion, which primarily relates to acquired in-process research and development
(IPR&D) of $8.3 billion, an amortizable intangible asset of $5.2 billion, goodwill of $2.9 billion and other current and non-current
assets of $1.1 billion. The fair value of the liabilities assumed is $3.0 billion, primarily related to deferred taxes. During the fiscal
fourth quarter of 2025, the U.S. FDA approved CAPLYTA as an adjunctive therapy with anti-depressants for the treatment of
major depressive disorder in adults. This IPR&D asset was reclassified to a definite lived asset and began amortizing in the fiscal
fourth quarter of 2025.
Asset acquisitions
If it is determined that the acquired set does not meet the definition of a business under the acquisition method of accounting, the
transaction is accounted for as an asset acquisition. In this case, no goodwill is recorded, acquired in-process research and
development (IPR&D) with no alternative future use is immediately recorded as research and development expense and contingent
consideration is recorded when the related event occurs.
Firefly Bio
On July 29, 2026, the Company completed the acquisition of Firefly Bio, Inc. (Firefly), a biotechnology company advancing its
proprietary Firelink™ degrader antibody conjugate (DAC) platform, for approximately $1.0 billion in cash. The Company recorded an
IPR&D charge of approximately $1.0 billion, and the results of operations are included in the Innovative Medicine segment as of the
acquisition date.
In the fiscal nine months of 2025, there were no material asset acquisitions.
In the fiscal nine months of 2026 and 2025, there were no material divestitures.
Other arrangements
Royalty Pharma
In the fiscal first quarter of 2026, the Company entered into a co-funding agreement with Royalty Pharma plc. (Royalty Pharma)
under which the Company will receive up to a total of $0.5 billion during the fiscal years 2026 and 2027 to support the clinical
development of JNJ-4804, a co-antibody therapy in development to treat chronic immune-mediated diseases. As there is a
substantive and genuine transfer of risk to Royalty Pharma, the development funding is recognized as an obligation to perform
contractual services. Accordingly, the funding the Company receives is recognized as a reduction to Research and development
expense as the Company performs its contractual services.
Table of Contents
Form 10-Q 29

-- 34 of 61 --

If successful, upon regulatory approval of certain indications in the U.S. or other major markets, Royalty Pharma will receive
approval-based fixed milestone payments up to approximately $0.5 billion and will also be eligible to receive sales-based milestone
payments and low-single digit royalties based on commercial sales. The funding received during the fiscal nine months of 2026 was
not material.
Sail Biomedicines
In the fiscal third quarter of 2026, the Company entered into strategic agreements and collaboration with Sail Biomedicines (Sail), a
biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. The Company is collaborating with Sail
to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application
of Sail's in vivo CAR-T platform across additional therapeutic targets over time. Under the terms of the agreements, the Company
made total initial payments of $0.8 billion, including a $0.5 billion equity investment recorded within Other assets, and the
remainder, primarily related to an option premium payment, is recorded within Other (income) and expense, net on the Consolidated
Statement of Earnings. On the Consolidated Statement of Cash Flows, the transaction of $0.8 billion is primarily recorded within
purchases of investments and the option premium is recorded as an adjustment to Net Earnings within Asset Write-downs.
Additionally, the Company has been granted an exclusive option to acquire Sail for approximately $2.6 billion.
Note 11 — Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual
property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from
time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be
incurred, and the amount of the loss can be reasonably estimated. As of September 27, 2026, the Company has determined that
the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued
for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new
information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters
discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of
loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about
future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to
make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in
the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete;
proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or
jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-
party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent
adverse awards, judgments, or verdicts have been rendered against the Company, the Company does not record an accrual until a
loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date, and discussions with counsel, the
ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material
adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these
matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that
period.
Matters concerning talc
As of September 27, 2026, there are approximately 76,500 plaintiffs in the United States with direct claims against the Company
and its affiliates in pending lawsuits regarding injuries allegedly due to the use of body powders containing talc, primarily
JOHNSON’S Baby Powder.
In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts
against the Company, many of which have been reversed on appeal. The Company continues to believe that it has strong legal
grounds to contest all the talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc
products, in certain circumstances the Company has settled cases.
In an effort to expeditiously resolve the litigation for the overwhelming majority of claimants, beginning in October 2021, the
Company underwent a series of corporate restructurings which ultimately resulted in two entities, Red River Talc, LLC (Red River)
and Pecos River Talc LLC (Pecos River), being assigned all liabilities related in any way to injury or damage, or alleged injury or
Table of Contents
30

-- 35 of 61 --

damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk
of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a
workers’ compensation statute or act. As a result of the restructurings, all claims in North America related to ovarian and other
gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit, and certain other claims in
North America were allocated to Pecos River. In connection with these restructurings, the Company filed a series of three Chapter
11 bankruptcy proceedings. Ultimately, each of the bankruptcy proceedings was dismissed and, as a result, the Company reversed
substantially all, or approximately $7.0 billion, from amounts previously reserved for the bankruptcy resolution in the fiscal first
quarter of 2025.
Following the third bankruptcy dismissal, litigation in the tort system recommenced with both ovarian cancer and mesothelioma
trials scheduled in various state courts throughout 2026 and beyond. In July 2026, following certain favorable rulings in the multi-
district litigation (MDL) pending in the United States District Court for the District of New Jersey and plaintiffs' withdrawal of their
causation experts in the first bellwether matters, the Company announced a plan to resolve the ovarian cancer docket. Specifically,
the Company reached an agreement with plaintiff firms leading the MDL and related state court proceedings conditioned on,
among other things, the express participation of at least 95% of the remaining claims. The proposed resolution calls for a
$5.5 billion commitment by the Company. The proposed agreement does not impact the mesothelioma docket, which remains
ongoing. The Company also faces litigation in Canada.
As of the third quarter of 2026, the total present value of the reserve for talc related matters is approximately $9.0 billion,
comprising the ovarian settlement agreement, executed settlement agreements, litigation defense, and other costs. Approximately
half of the reserve is recorded as a current liability.
In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States
District Court for the District of New Jersey alleging that the Company violated the federal securities laws by failing to disclose
alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the
Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the
court denied, in part, the motion to dismiss. In December 2023, the court granted plaintiffs’ motion for class certification. In July
2025, the Third Circuit affirmed the court's order granting class certification. In September 2025, the Company petitioned the
Third Circuit for rehearing or rehearing en banc, which was denied in October 2025. In February 2026, the Company filed a writ of
certiorari with the United States Supreme Court regarding the Third Circuit’s decision, which the Supreme Court denied in April
2026. Expert discovery is proceeding.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc., and two of its affiliates, Imerys Talc Vermont, Inc. and
Imerys Talc Canada, Inc. (collectively, Imerys), filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the
United States Bankruptcy Court for the District of Delaware. In February 2021, Cyprus Mines Corporation (Cyprus), which sold
certain talc mines and assets to Imerys, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware
Bankruptcy Court. In July 2024, the Company, Imerys, Cyprus, and certain of their affiliates (including their parent entities), and the
tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective
Chapter 11 cases, entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties' ongoing
disputes, including disputes raised in the Imerys and Cyprus bankruptcies regarding (i) the Company's alleged obligations to
indemnify Imerys and Cyprus for personal injury claims allegedly caused by exposure to talc contained in the Company's products
and (ii) entitlements to proceeds of certain of the Company's insurance policies. In October 2024, the Delaware Bankruptcy Court
entered an order approving the Imerys Settlement Agreement (the Settlement Order). Certain insurers appealed the Settlement
Order and sought a stay of the Settlement Order pending appeal, which the Delaware Bankruptcy Court denied in January 2025. In
August 2025, the United States District Court for the District of Delaware denied the insurers' appeal of the Settlement Order. The
insurers appealed that decision and, in October 2026, the Third Circuit dismissed the appeal.
Intellectual property
Certain subsidiaries of the Company are involved in legal proceedings and claims related to patent, trademark, and other intellectual
property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents
that relate to various products and/or to allegations that certain of the Company’s products infringe the intellectual property rights
of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with
respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could
adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity,
require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated
intangible asset.
Table of Contents
Form 10-Q 31

-- 36 of 61 --

Innovative Medicine
INVEGA SUSTENNA
Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) filed patent
infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to
market generic versions of INVEGA SUSTENNA before expiration of the Orange Book listed patent. The following entities are
named defendants: Eugia Pharma Specialities Ltd. and Eugia US, LLC. The following U.S. patent is included: 9,439,906. In June
2026, Janssen entered into a confidential settlement with Eugia Pharma Specialities Ltd. and Eugia US, LLC.
Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the
Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to
market generic versions of INVEGA SUSTENNA before expiration of the listed patent. Pharmascience Inc. is a named defendant.
The following Canadian patent is included in one or more cases: 2,655,335. In September 2024, the Supreme Court of Canada
granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid. In July 2026, the
Supreme Court of Canada dismissed Pharmascience's appeal.
ERLEADA
Beginning in January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc. (collectively, Janssen Inc.), and Sloan-Kettering Institute for
Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance)
Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz’s filing of ANDSs seeking approval to market 60 mg and
240 mg generic versions of ERLEADA before the expiration of CA Patent Nos. 3,008,345; 2,875,767; 2,885,415; and 3,128,331.
Janssen Inc. and SKI are seeking orders enjoining Sandoz from marketing 60 mg and 240 mg generic versions of ERLEADA before
the expiration of the relevant patents. Trial took place in August and September 2026. A decision is pending.
Beginning in June 2026, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., and Sloan-Kettering Institute for Cancer Research
initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN
Pharmaceuticals Inc., MSN Laboratories Private Limited, and Novadoz Pharmaceuticals, LLC who filed an ANDA seeking approval to
market 60 mg and 240 mg generic versions of ERLEADA before the expiration of certain Orange Book listed patents. The following
U.S. patents are included in the case: 9,481,663; 11,963,952; 12,303,493; and 12,303,497.
Beginning in October 2026, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. initiated a patent infringement lawsuit in the
United States District Court for the District of New Jersey against Lupin Limited and Lupin Pharmaceuticals, Inc. who filed an
ANDA seeking approval to market 60 mg generic versions of ERLEADA before the expiration of certain Orange Book listed patents.
The following U.S. patents are included in the case: 12,303,493 and 12,303,497.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United
States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of
SPRAVATO before expiration of certain Orange Book listed patents. The following entities are named defendants: Sandoz Inc.
(Sandoz) and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134;
11,311,500; and 11,446,260. A trial against Sandoz took place in February 2026. In August 2026, the United States District Court
for the District of New Jersey issued a decision finding that the asserted patents are infringed and not invalid. In September 2026,
Sandoz appealed.
CAPLYTA
Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States
District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market
generic versions of CAPLYTA before expiration of certain Orange Book listed patents. The following entities are named
defendants: Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Ltd. The following U.S. patents are included: RE 48,825; RE
48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419;
11,980,617; 12,070,459; 12,090,155; 12,122,792; 12,128,043; 12,409,176; and 12,410,195. In August 2026, Intra-Cellular, Zydus
Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. entered into a confidential settlement agreement and the case was
dismissed.
Table of Contents
32

-- 37 of 61 --

CARVYKTI
In January 2026, 2seventy bio, Inc. filed suit in the Unified Patent Court, Local Division of Brussels, against the Company, Janssen
Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag NV, Janssen
Biologics B.V., Janssen-Cilag B.V., Janssen-Cilag GmbH, Janssen-Cilag, Janssen-Cilag SpA, Janssen-Cilag A/S, Janssen-Cilag
Aktiebolag, Janssen-Cilag Farmaceutica Lda., Legend Biotech Corporation, Legend Biotech USA Inc., Legend Biotech Ireland
Limited, and Legend Biotech Belgium BV alleging that the manufacture and sale of CARVYKTI infringes EU Patent No. 3 689 383.
In the suit, the exclusive licensee, 2seventy bio, Inc., seeks damages and an injunction. In May 2026, The United States of America,
including the Department of Health and Human Services, Office of Technology Transfer, as the patent owner, intervened in the
action. An oral hearing is scheduled for March 2027.
DARZALEX
In February 2026, BIOCAD JSC (BIOCAD) and PK-137 LLC filed a lawsuit against Genmab A/S and Johnson & Johnson LLC in the
Arbitrazh Court of Moscow Region seeking: (1) a declaration of entitlement to use the inventions claimed in Genmab’s EA Patent
No. 015584 in the manufacture/marketing of their drug “Daratumia” (INN daratumumab) starting from March 24, 2026, on the
basis that patent EA 015584 expires March 23, 2026; (2) a declaration that Genmab’s and Johnson & Johnson LLC’s actions in
obtaining PTE extending Genmab’s EA Patent No. 037929 and sending warning letters to BIOCAD asserting infringement risks
after March 24, 2026 constitute unfair competition under Article 14.8 of Law on Protection of Competition (EA 037929 has PTE
until March 23, 2031); and (3) an order restraining Genmab and Johnson & Johnson LLC from creating obstacles to BIOCAD’s
introduction of “Daratumia” into civil circulation starting from March 24, 2026. In September 2026, BIOCAD and PK-137 LLC
withdrew their unfair competition claim and BIOCAD launched its biosimilar daratumumab product at risk.
SIMPONI
In March 2026, Janssen Biotech, Inc. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) filed a patent
infringement lawsuit in the United States District Court for the District of Delaware against Accord BioPharma, Inc. (Accord) and
Bio-Thera Solutions, Ltd. (Bio-Thera) in response to Accord’s filing of an aBLA seeking approval to market biosimilar versions of
SIMPONI and SIMPONI ARIA and providing notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A) for those biosimilar
products. The following U.S. patents are included in the case: 8,017,325; 8,586,356; 8,852,889; 8,956,830; 9,170,249; 9,217,168;
9,475,858; 9,487,810; 9,663,810; 9,890,410; 12,129,292; 12,139,735; and 12,180,271. The following U.S. patents were dismissed
without prejudice: 11,014,982; 11,041,020; 12,122,824; and 12,291,566. Janssen sought an order enjoining defendants from
marketing their biosimilar versions of SIMPONI and SIMPONI ARIA before the expiration of the asserted patents. In September
2026, the court preliminarily enjoined Accord and Bio-Thera pending trial. Trial is scheduled for March 2028. Accord and Bio-Thera
appealed the injunction.
In March 2026, Accord BioPharma, Inc., Intas Pharmaceuticals Ltd., and Bio-Thera Solutions, Ltd. submitted four petitions
requesting inter partes review (IPR) of U.S. patent nos. 11,014,982; 11,041,020; 12,122,824; and 12,291,566. In September 2026, the
U.S. Patent & Trademark Office instituted review of the patents. A final written decision is expected by September 2027.
In June 2026, Janssen Biotech, Inc. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) filed a patent
infringement lawsuit in the United States District Court for the Eastern District of Virginia against Alvotech hf. and Alvotech USA
Inc. (Alvotech USA) in response to Alvotech USA’s filing of aBLAs seeking approval to market biosimilar versions of SIMPONI and
SIMPONI ARIA and providing notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A) for those biosimilar products.
The following U.S. patents are included in the case: 8,017,325; 8,852,889; 8,956,830; 9,170,249; 9,217,168; 9,475,858; 9,487,810;
9,663,810; 9,890,410; 10,421,986; 11,225,516; 12,139,735; 12,534,524; and 12,595,454. Janssen is seeking an order enjoining
defendants from marketing their biosimilar versions of SIMPONI and SIMPONI ARIA before the expiration of the asserted patents.
In July 2026, Janssen filed a motion for preliminary injunction pending trial. In September 2026, Teva Pharmaceuticals USA Inc.
intervened seeking a declaratory judgment of noninfringement and invalidity. No trial date has been set.
MedTech
In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the United States
District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents.
Maquet counterclaimed for infringement against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. The following U.S.
patents are at issue: 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. In February 2026, the U.S. Court of Appeals for
the Federal Circuit remanded the case after considering the district court's claim constructions. Discovery will begin based on the
altered constructions.
Table of Contents
Form 10-Q 33

-- 38 of 61 --

In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH in
the United States District Court for the District of Massachusetts alleging that certain Impella products infringe Maquet patents.
U.S. Patent No. 10,238,783 remains in the suit, and trial was held in May 2026. The jury returned a verdict in Abiomed's favor. Post-
trial motions are pending.
Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are
subject to extensive regulation by national, state, and local government agencies in the United States and other countries in which
they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation
brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and
substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In June 2026, three Relators filed an Amended False Claims Act Complaint in the United States District Court for the Southern
District of Florida alleging the Company and DePuy Synthes, along with Tenet Healthcare Corporation, Delray Medical Center, and
West Boca Medical Center caused the submission of false claims to federal and Florida healthcare programs. The Relators are sales
representatives for competitor companies, and the complaint was served following a decision by the Department of Justice to
decline intervening in the case. The Company and DePuy Synthes disagree with and are defending themselves against these claims.
Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in
the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA
and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under
seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the
relators. The court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in
part in January 2022, and trial commenced in May 2024. In June 2024, a jury found no liability regarding the anti-kickback
violations but found liability for a portion of the off-label promotion claims. The Company challenged the verdict on the off-label
claims in post-trial briefing. In March 2025, the court dismissed the state law portion of the claims but entered judgment on the
federal claims. The Company appealed the remainder of the verdict to the Third Circuit. The federal government has intervened for
the limited purpose of defending the qui tam provision of the False Claims Act. Briefing is complete and oral argument was held in
March 2026. A decision is pending. In April 2026, the Third Circuit ordered the parties to engage in mediation.
In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice
(DOJ) regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and
gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the DOJ notified JBI that it was closing
the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims
Act complaint, which was served on the Company. The DOJ declined to intervene in the qui tam lawsuit in August 2019. In
September 2026, the court denied relator/plaintiff's motion for summary judgment and granted the Company's motion for
summary judgment in full, thus obviating the need for a trial. Relator/plaintiff has until October 30, 2026 to file a notice of appeal.
General litigation
The Company or its subsidiaries regularly face claims in legal proceedings related to contracts, trade secrets, antitrust, unfair
competition, consumer protection, and environmental issues, the most significant of which are listed below. Although the Company
and its subsidiaries believe that they have substantial defenses to these cases, there can be no assurance as to the outcome of
these matters. A loss in any of these cases could require the payment of damages, injunctions, and/or other relief.
In October 2017, certain United States service members, civilians, and their families brought a complaint against a number of
pharmaceutical and medical devices companies, including the Company and certain of its subsidiaries in the United States District
Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint
alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical
and medical device contracts with the Iraqi Ministry of Health. In July 2020, the district court dismissed the operative complaint. In
January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the district court’s decision. In June
2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit for reconsideration. In
January 2026, the D.C. Circuit affirmed its reversal of the district court's dismissal of the complaint. In August 2026, defendants
Table of Contents
34

-- 39 of 61 --

filed a petition for a writ of certiorari to the Supreme Court. In September 2026, defendants filed an additional motion to dismiss
certain claims in the operative complaint.
In September 2026, additional United States service members, civilians, and their families filed an action against the same
defendants in the United States District Court for the District of Columbia alleging similar claims, including violation of the Anti-
Terrorism Act.
In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson &
Johnson in the United States District Court for the District of New Jersey. The complaint alleges that the defendants breached
fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s
prescription-drug benefits program. The complaint seeks damages and other relief. In March 2025, plaintiffs filed a second
amended complaint. In November 2025, the court granted defendants' motion to dismiss plaintiffs' fiduciary duty claims. Plaintiffs
voluntarily withdrew their remaining claim, and the court entered final judgment in defendants' favor in January 2026. Plaintiffs
appealed to the United States Court of Appeals for the Third Circuit.
MedTech
In October 2020, Fortis Advisors LLC, as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint
against the Company alleging breach of contract, fraud, and other causes of action in connection with Ethicon’s acquisition of Auris
in 2019. In January 2026, the Company paid a $0.8 billion judgment, inclusive of interest.
In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court
for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate
the antitrust laws of the United States and the State of California by restricting competition in the sale of High-Density Mapping
Catheters and Ultrasound Catheters. In May 2025, a jury returned its verdict in favor of Innovative Health. In August 2025, the
court issued a permanent injunction concerning BWI's business practices. BWI appealed both the jury verdict and the permanent
injunction. In June 2026, briefing of the appeal was completed.
Innovative Medicine
In October 2018, two separate putative class actions were filed against Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals
US, Inc. and Actelion Clinical Research, Inc. (collectively, Actelion) in the United States District Court for the District of Maryland
and the United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal
antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of
TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration,
which imposes restrictions on distribution of the product. In January 2019, plaintiffs dismissed the District of Columbia case and
filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district
court granted plaintiffs' motion for class certification. In February 2026, the parties agreed to settle the matter. In July 2026, the
court granted final approval of the settlement.
In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively, Janssen) in
the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state
antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent
rights covering STELARA. The complaint seeks damages and other relief. In August 2024, the court granted in part and denied in
part Janssen's motion to dismiss plaintiffs' amended complaint. In December 2025, the court granted plaintiffs' motion for class
certification. In January 2026, the court granted summary judgment for Janssen on plaintiffs' claim regarding patents obtained
through the acquisition of Momenta Pharmaceuticals, Inc. in 2020. In March 2026, plaintiffs appealed to the United States Court
of Appeals for the Fourth Circuit.
In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, and the Company
(collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of
Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing
information for ZYTIGA to the government in connection with direct sales and reimbursement programs. The federal and state
governments have declined to intervene, and the lawsuit is being prosecuted by the relator. In December 2021, the United States
District Court for the District of New Jersey denied Janssen's motion to dismiss. Daubert proceedings are ongoing.
In August 2025, Xoma Corporation (Xoma) filed a complaint against Janssen Biotech, Inc. (Janssen) in the United States District
Court for the Eastern District of Pennsylvania. The complaint alleges breach of contract, unjust enrichment, and declaratory relief
Table of Contents
Form 10-Q 35

-- 40 of 61 --

claims against Janssen regarding the alleged failure to obtain a license from Xoma in connection with Janssen's commercialization
of TREMFYA. In December 2025, the court denied Janssen's motion to dismiss.
Note 12 — Restructuring
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative
Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The pre-tax
restructuring expense in the fiscal third quarter of 2026 primarily related to exit costs. Total project costs of approximately
$0.3 billion have been recorded since the restructuring was announced. The program is expected to be substantially complete by
the end of 2029 with estimated costs between $0.7 billion and $0.8 billion, and include site and supplier exit costs,
decommissioning and asset impairments costs.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and
focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The pre-tax
restructuring expense in the fiscal third quarter of 2026 and 2025 primarily included costs related to product exits. Total project
costs of approximately $0.4 billion have been recorded since the restructuring was announced. This program will be completed as
of the fiscal fourth quarter of 2026 at a total project cost of approximately $0.6 billion.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to
streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring
expense in the fiscal third quarter of 2026 primarily included costs related to market and product exits. The pre-tax restructuring
expense in the fiscal third quarter of 2025 primarily included asset impairments as well as market and product exits. Total project
costs of approximately $0.9 billion have been recorded since the restructuring was announced. This program will be completed as
of the fourth quarter of 2026 at a total cost of approximately $1.0 billion.
The following table summarizes the restructuring expenses for 2026 and 2025:
(Pre-tax Dollars in Millions) Q3 2026 Q3 2025 Q3 YTD 2026 Q3 YTD 2025
Innovative Medicine supply chain(1) $74 — 274 —
MedTech Segment Surgery franchise(2) 80 128 194 157
MedTech Segment Orthopaedics franchise(3) 41 40 65 145
Total Programs $195 168 533 302
(1) Included $103 million in Restructuring, a reversal of $18 million expense in Cost of products sold and a reversal of $11 million expense in Other
(Income)/Expense on the Consolidated Statement of Earnings in the fiscal third quarter of 2026. Included $171 million in Other (Income)/
Expense and $103 million in Restructuring on the Consolidated Statement of Earnings in the fiscal nine months of 2026.
(2) Included $44 million in Restructuring, $6 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated
Statement of Earnings in the fiscal third quarter of 2026. Included $105 million in Restructuring, $30 million in Cost of products sold and
$59 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal nine months of 2026. Included $35 million in
Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings in the fiscal third quarter of 2025.
Included $64 million in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings in the fiscal nine
months of 2025.
(3) Included $34 million in Restructuring and $7 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal third
quarter of 2026. Included $39 million in Restructuring, $25 million in Cost of products sold and $1 million in Other (Income)/Expense on the
Consolidated Statement of Earnings in the fiscal nine months of 2026. Included $28 million in Restructuring and $12 million in Cost of products
sold on the Consolidated Statement of Earnings in the fiscal third quarter of 2025. Included $80 million in Restructuring, $35 million in Cost of
products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal nine months of 2025.
Restructuring reserves as of September 27, 2026 and December 28, 2025 were insignificant.
Table of Contents
36

-- 41 of 61 --

Item 2 — Management’s discussion and analysis of financial
condition and results of operations
Results of operations
Sales to customers
Analysis of consolidated sales
For the fiscal nine months of 2026, worldwide sales were $74.8 billion, a total increase of 7.4%, including an operational* increase
of 6.0% as compared to 2025 fiscal nine months sales of $69.6 billion. Currency fluctuations had a positive impact of 1.4% for the
fiscal nine months of 2026. In the fiscal nine months of 2026, acquisitions and divestitures had a net positive impact of 0.3%, on
worldwide operational sales growth, primarily related to CAPLYTA. In the fiscal nine months of 2026, the negative impact of the
STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 4.7%.
Sales by U.S. companies were $42.8 billion in the fiscal nine months of 2026, which represented an increase of 8.3% as compared
to the prior year. In the fiscal nine months of 2026, acquisitions and divestitures had net positive impact of 0.7% on U.S. operational
sales growth, primarily related to CAPLYTA. In the fiscal nine months of 2026, the negative impact of the STELARA sales decline,
due to biosimilar competition on U.S. operational sales was approximately 6.6%. Sales by international companies were $31.9 billion,
which represented an increase of 6.2%, including an operational increase of 3.0%, and a positive currency impact of 3.2% as
compared to the fiscal nine months sales of 2025. In the fiscal nine months of 2026, the net impact of acquisitions and divestitures
on international operational sales growth was a negative 0.1%. In the fiscal nine months of 2026, the negative impact of the
STELARA sales decline, due to biosimilar competition, on international operational sales was approximately 2.4%.
In the fiscal nine months of 2026, sales by companies in Europe achieved growth of 6.5%, which included an operational increase of
2.3% and a positive currency impact of 4.2%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth
of 10.6%, which included an operational increase of 4.5% and a positive currency impact of 6.1%. Sales by companies in the Asia-
Pacific, Africa region achieved growth of 4.3%, including operational growth of 3.6% and a positive currency impact of 0.7%.
Fiscal nine months 2026
sales by geographic region (in billions)
$17.0
$4.0
$11.0
$42.8
Europe
Western
Hemisphere
(ex. U.S.)
Asia-Pacific,
Africa
U.S.
Fiscal nine months 2026
sales by segment (in billions)
$48.6
$26.2
Innovative
Medicine
MedTech
Note: values may have been rounded
*operational excludes the effect of translational currency
Table of Contents
Form 10-Q 37

-- 42 of 61 --

For the fiscal third quarter of 2026, worldwide sales were $25.4 billion, a total increase of 5.9%, which included operational growth
of 6.0% and a negative currency impact of 0.1% as compared to 2025 fiscal third quarter sales of $24.0 billion. In the fiscal third
quarter of 2026, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.1%. In the
fiscal third quarter of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide
operational sales was approximately 4.2%.
Sales by U.S. companies were $15.0 billion in the fiscal third quarter of 2026, which represented an increase of 9.1% as compared to
the prior year. In the fiscal third quarter of 2026, there was no net impact from acquisitions and divestitures on U.S. operational
sales growth. In the fiscal third quarter of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition
on U.S. operational sales was approximately 5.9%. Sales by international companies were $10.4 billion, a total increase of 1.5%,
which included operational growth of 1.8% and a negative currency impact of 0.3%. In the fiscal third quarter of 2026, the net
impact of acquisitions and divestitures on international operational sales growth was a negative 0.1%. In the fiscal third quarter of
2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on international operational sales was
approximately 2.1%.
In the fiscal third quarter of 2026, sales by companies in Europe experienced a sales decline of 0.6%, which included operational
growth of 1.0% offset by a negative currency impact of 1.6%. Sales by companies in the Western Hemisphere, excluding the U.S.,
achieved growth of 12.5%, which included operational growth of 8.0% and a positive currency impact of 4.5%. Sales by companies
in the Asia-Pacific, Africa region achieved growth of 1.0%, which included operational growth of 1.0% and 0.0% impact from
currency.
Q3 2026
Sales by Geographic Region (in billions)
$5.4
$1.4
$3.7
$15.0
Europe
Western
Hemisphere
(ex. U.S.)
Asia-Pacific,
Africa
U.S.
Q3 2026
Sales by Segment (in billions)
$16.8
$8.6
Innovative
Medicine
MedTech
Note: values may have been rounded
Table of Contents
38

-- 43 of 61 --

Analysis of sales by business segments
Innovative Medicine
Innovative Medicine segment sales in the fiscal nine months of 2026 were $48.6 billion, an increase of 8.8% as compared to the
same period a year ago, with an operational increase of 7.4% and a positive currency impact of 1.4%. U.S. Innovative Medicine sales
increased 9.9% as compared to the same period a year ago. International Innovative Medicine sales increased by 7.2%, including an
operational increase of 3.6% and a positive currency impact of 3.6%. In the fiscal nine months of 2026, the net impact of
acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a positive 0.5%, primarily related to
CAPLYTA. In the fiscal nine months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, was
an approximate 7.8%, 10.4% and 4.2% on worldwide, U.S. and international Innovative Medicine segment operational sales,
respectively.
Major Innovative Medicine therapeutic area sales — Fiscal Nine Months Ended
(Dollars in Millions)
September
27, 2026
September
28, 2025
Total
Change
Operations
Change
Currency
Change
Oncology $21,981 $18,519 18.7 % 16.8 % 1.9 %
DARZALEX 12,410 10,448 18.8 17.0 1.8
CARVYKTI 1,964 1,332 47.4 45.5 1.9
TECVAYLI 774 494 56.7 55.7 1.0
TALVEY 497 314 58.3 57.5 0.8
RYBREVANT/ LAZCLUZE 866 518 67.4 67.5 (0.1)
ERLEADA 2,967 2,615 13.5 10.8 2.7
IMBRUVICA 1,822 2,139 (14.8) (17.5) 2.7
Other Oncology(1) 680 659 3.2 2.9 0.3
Immunology 11,445 11,868 (3.6) (4.8) 1.2
TREMFYA 6,050 3,566 69.7 67.9 1.8
SIMPONI/ SIMPONI ARIA 1,833 2,036 (10.0) (11.6) 1.6
REMICADE 1,154 1,398 (17.5) (18.4) 0.9
STELARA 2,112 4,848 (56.4) (57.2) 0.8
Other Immunology 297 21 * * *
Neuroscience 6,887 5,722 20.3 19.5 0.8
SPRAVATO 1,676 1,193 40.5 39.7 0.8
CAPLYTA(2) 1,029 451 * * —
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 3,051 2,824 8.0 7.4 0.6
CONCERTA/methylphenidate 425 452 (5.9) (7.0) 1.1
Other Neuroscience 706 803 (12.1) (14.2) 2.1
Pulmonary Hypertension 3,175 3,253 (2.4) (3.0) 0.6
UPTRAVI 1,460 1,411 3.5 2.6 0.9
OPSUMIT/ OPSYNVI 1,580 1,682 (6.1) (6.6) 0.5
Other Pulmonary Hypertension 135 160 (15.6) (15.4) (0.2)
Infectious Diseases 2,465 2,434 1.3 (1.1) 2.4
EDURANT/rilpivirine 1,145 1,103 3.8 0.0 3.8
PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 1,196 1,196 0.0 (0.9) 0.9
Other Infectious Diseases 124 135 (8.2) (11.7) 3.5
Cardiovascular / Metabolism / Other 2,614 2,842 (8.0) (8.5) 0.5
XARELTO 1,959 1,946 0.7 0.7 —
Other 655 896 (26.9) (28.5) 1.6
Total Innovative Medicine Sales $48,567 $44,638 8.8% 7.4% 1.4 %
Table of Contents
Form 10-Q 39

-- 44 of 61 --

Innovative Medicine segment sales in the fiscal third quarter of 2026 were $16.8 billion, an increase of 7.7% as compared to the
same period a year ago, including an operational increase of 7.9% and a negative currency impact of 0.2%. U.S. Innovative Medicine
sales increased 11.1% as compared to the same period a year ago. International Innovative Medicine sales increased by 2.4%,
including an operational increase of 3.0% and a negative currency impact of 0.6%. In the fiscal third quarter of 2026, the impact of
divestitures on the worldwide Innovative Medicine segment operational sales growth was a negative 0.1%. In the fiscal third quarter
of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, was an approximate 6.9%, 9.2% and
3.8% on worldwide, U.S. and international Innovative Medicine segment operational sales, respectively.
Major Innovative Medicine therapeutic area sales — Fiscal Third Quarter Ended
(Dollars in Millions)
September
27, 2026
September
28, 2025
Total
Change
Operations
Change
Currency
Change
Oncology $7,602 $6,529 16.4 % 16.7 % (0.3) %
DARZALEX 4,239 3,672 15.4 15.6 (0.2)
CARVYKTI 710 524 35.5 35.2 0.3
TECVAYLI 312 177 76.6 77.3 (0.7)
TALVEY 171 122 40.9 42.1 (1.2)
RYBREVANT/ LAZCLUZE 320 198 62.3 63.5 (1.2)
ERLEADA 1,023 936 9.4 9.4 0.0
IMBRUVICA 563 695 (18.8) (18.4) (0.4)
Other Oncology(1) 262 207 26.3 26.7 (0.4)
Immunology 4,221 4,168 1.3 1.4 (0.1)
TREMFYA 2,396 1,424 68.3 68.2 0.1
SIMPONI/ SIMPONI ARIA 568 687 (17.3) (17.1) (0.2)
REMICADE 394 476 (17.3) (17.6) 0.3
STELARA 716 1,570 (54.4) (54.0) (0.4)
Other Immunology 147 12 * * *
Neuroscience 2,375 2,024 17.3 17.6 (0.3)
SPRAVATO 624 459 36.1 36.0 0.1
CAPLYTA 398 240 66.1 66.1 —
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA 998 929 7.3 7.5 (0.2)
CONCERTA/ methylphenidate 143 140 2.1 2.9 (0.8)
Other Neuroscience 212 256 (17.3) (16.2) (1.1)
Pulmonary Hypertension 897 1,115 (19.5) (19.2) (0.3)
UPTRAVI 483 484 (0.1) (0.2) 0.1
OPSUMIT/ OPSYNVI 372 578 (35.7) (35.2) (0.5)
Other Pulmonary Hypertension 42 53 (19.7) (17.7) (2.0)
Infectious Diseases 813 829 (1.8) (1.1) (0.7)
EDURANT/rilpivirine 386 385 0.4 1.8 (1.4)
PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA 381 397 (3.8) (3.6) (0.2)
Other Infectious Diseases 46 47 (3.0) (4.5) 1.5
Cardiovascular / Metabolism / Other 849 899 (5.6) (5.5) (0.1)
XARELTO 653 635 2.7 2.7 —
Other 197 264 (25.5) (25.3) (0.2)
Total Innovative Medicine Sales $16,757 $15,563 7.7% 7.9% (0.2) %
*percentage greater than 100% or not meaningful
(1) Includes sales of ZYTIGA which were previously disclosed separately
(2) Acquired with Intra-Cellular Therapies on April 2, 2025
Table of Contents
40

-- 45 of 61 --

Oncology products achieved operational sales growth of 16.7% as compared to the same period a year ago. Contributors to the
growth were: DARZALEX (daratumumab) driven by strong share gains and market growth, CARVYKTI (ciltacabtagene autoleucel)
driven by share gains and continued site expansion, TECVAYLI (teclistamab-cqyv) driven by share gains from the U.S. TECVAYLI +
DARZALEX FASPRO approval, TALVEY (talquetamab-tgvs) driven by share gains from expansion in the community setting,
RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) driven by launch uptake and share gains, ERLEADA (apalutamide) due to
continued share gains and market growth partially offset by unfavorable patient mix and Other Oncology driven by the U.S. launch
uptake of INLEXZO (gemcitabine intravesical system). Growth was partially offset by a decline in IMBRUVICA (ibrutinib) sales due
to share loss from competitive pressures and unfavorable patient mix.
Immunology products achieved operational sales growth of 1.4% as compared to the same period a year ago due to the growth of
TREMFYA (guselkumab) driven by share gains across all indications with significant IBD launch momentum and market growth as
well as growth in Other Immunology driven by IMAAVY (nipocalimab) and ICOTYDE (icotrokinra) launch uptake in the U.S. Growth
was partially offset by a decline of STELARA (ustekinumab) driven by the impact of biosimilar competition and increasing adoption
of novel classes as well as declines of SIMPONI/SIMPONI ARIA (golimumab) and REMICADE (infliximab) driven by share loss,
biosimilar competition, and unfavorable patient mix partially offset by market growth.
The Company expects STELARA biosimilars to continue to negatively impact the Company’s sales of STELARA. Biosimilars for
SIMPONI have entered the European market in the second quarter of 2026, with a potential U.S. entrant later in 2026. This will
likely result in a reduction in future sales.
Neuroscience products achieved operational growth of 17.6% as compared to the same period a year ago. The sales growth of
SPRAVATO (esketamine) was driven by continued share gains, supported by increased patient demand due to strong physician
adoption. Growth of CAPLYTA (lumateperone) was driven by strong continued momentum in the adjunctive treatment of Major
Depressive Disorder (aMDD) launch and continued demand across bipolar disorder and schizophrenia. Growth of INVEGA
SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA was primarily driven by favorable patient and inventory dynamics partially
offset by share loss.
Pulmonary Hypertension products experienced an operational sales decline of 19.2% as compared to the same period a year ago.
The sales of UPTRAVI (selexipag) were flat due to unfavorable patient mix partially offset by market and share growth. There are
potential generic entrants in 2027 in the U.S. and Europe which will likely result in a reduction in future sales. The sales decline of
OPSUMIT (macitentan)/OPSYNVI (macitentan/tadalafil) was driven by lower demand following U.S. generic entrants late in the
second quarter of 2026. There are potential generic entrants in 2027 in Europe which will likely result in a reduction in future sales.
Infectious disease products experienced an operational sales decline of 1.1% as compared to the same period a year ago. The sales
decrease of PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA was driven by declines in share and market partially offset by
favorable patient mix.
Cardiovascular / Metabolism / Other products experienced an operational sales decline of 5.5% as compared to the same period a
year ago. The sales decline was partially offset by an increase in XARELTO (rivaroxaban) sales primarily driven by favorable patient
mix partially offset by continued share erosion. There are potential generic entrants in 2027 in the U.S. which will likely result in a
reduction in future sales.
The Company recently announced a policy revising the 340B pricing offer on its covered outpatient drugs to require covered
entities to submit limited, commercially standard claims data for each 340B-eligible drug dispense or administration. Subject to
each covered entity’s submission of appropriate claims data, the Company will continue to offer the covered entity access to 340B
pricing on the Company’s covered outpatient drugs up-front at the time of purchase. The Company also recently updated its 340B
contract pharmacy policy, which permits covered entities to designate up to one contract pharmacy for dispensing of the
Company’s 340B-priced covered outpatient drugs. A covered entity may continue to purchase and receive 340B pricing on such
drugs dispensed or administered at its own eligible locations. Both policies include exceptions for certain covered entities.
The Company believes these policies are necessary to identify and address duplicate discounts, diversion, and other non-
compliance and improve program oversight and dispute resolution. The 340B Drug Pricing Program is a U.S. federal government
program that requires drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities as a
condition of manufacturers receiving reimbursement for their drugs under Medicaid and Medicare Part B.
Table of Contents
Form 10-Q 41

-- 46 of 61 --

MedTech
The MedTech segment sales in the fiscal nine months of 2026 were $26.2 billion, an increase of 4.9% as compared to the same
period a year ago, with an operational increase of 3.5% and a positive currency impact of 1.4%. U.S. MedTech sales increased by
4.8%. International MedTech sales increased by 4.9%, including an operational increase of 2.2% and a positive currency impact of
2.7%. In the fiscal nine months of 2026, the net impact of acquisitions and divestitures on the MedTech segment operational sales
growth was a negative 0.1%.
Major MedTech franchise sales — Fiscal Nine Months Ended
(Dollars in Millions)
September
27, 2026
September
28, 2025
Total
Change
Operations
Change
Currency
Change
Cardiovascular $7,088 $6,629 6.9 % 5.8 % 1.1 %
Electrophysiology 4,509 4,209 7.1 5.6 1.5
Abiomed 1,340 1,291 3.8 3.5 0.3
Shockwave 965 828 16.6 16.6 0.0
Other Cardiovascular 273 302 (9.4) (11.3) 1.9
Surgery 7,692 7,493 2.7 0.8 1.9
Advanced 3,467 3,402 1.9 0.2 1.7
General 4,225 4,092 3.3 1.3 2.0
Vision 4,277 4,048 5.6 4.8 0.8
Contact Lenses/Other 3,047 2,902 5.0 4.4 0.6
Surgical 1,230 1,147 7.3 5.9 1.4
Orthopaedics 7,146 6,820 4.8 3.6 1.2
Hips 1,296 1,235 4.9 3.6 1.3
Knees 1,216 1,155 5.3 4.2 1.1
Trauma 2,504 2,333 7.3 6.2 1.1
Spine, Sports & Other 2,131 2,096 1.7 0.4 1.3
Total MedTech Sales $26,204 $24,991 4.9% 3.5% 1.4 %
Table of Contents
42

-- 47 of 61 --

MedTech segment sales in the fiscal third quarter of 2026 were $8.6 billion, an increase of 2.5% as compared to the same period a
year ago, which included operational growth of 2.5% and currency impact of 0.0%. U.S. MedTech sales increased by 4.8%.
International MedTech sales increased by 0.1%, including operational growth of 0.1% and a currency impact of 0.0%. In the fiscal
third quarter of 2026, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was 0.0%.
Major MedTech franchise sales — Fiscal Third Quarter Ended
(Dollars in Millions)
September
27, 2026
September
28, 2025
Total
Change
Operations
Change
Currency
Change
Cardiovascular $2,307 $2,213 4.3 % 4.1% 0.2 %
Electrophysiology 1,487 1,418 4.9 4.4 0.5
Abiomed 412 423 (2.3) (1.5) (0.8)
Shockwave 325 278 16.8 17.2 (0.4)
Other Cardiovascular 81 95 (13.9) (14.7) 0.8
Surgery 2,528 2,542 (0.6) (1.0) 0.4
Advanced 1,155 1,165 (0.9) (1.3) 0.4
General 1,373 1,378 (0.3) (0.8) 0.5
Vision 1,461 1,400 4.4 5.1 (0.7)
Contact Lenses/Other 1,053 1,018 3.5 4.3 (0.8)
Surgical 408 383 6.8 7.1 (0.3)
Orthopaedics 2,345 2,274 3.2 3.4 (0.2)
Hips 419 405 3.1 3.3 (0.2)
Knees 386 377 2.5 3.1 (0.6)
Trauma 844 793 6.4 6.5 (0.1)
Spine, Sports & Other 697 698 (0.1) 0.1 (0.2)
Total MedTech Sales $8,642 $8,430 2.5% 2.5% 0.0 %
The Cardiovascular franchise achieved operational sales growth of 4.1% as compared to the prior year fiscal third quarter.
Electrophysiology sales growth was driven by procedure growth, commercial execution and new product performance (VARIPULSE,
TRUPULSE, CRYSTAL and DUAL ENERGY STSF) partially offset by competitive pressures in Pulsed Field Ablation catheters and
inventory dynamics outside the U.S. Abiomed sales decline was driven by lower patient volumes partially offset by sustained
adoption of Impella 5.5. Shockwave sales growth was driven by strong adoption of Coronary and Peripheral portfolios and new
product launches.
The Surgery franchise experienced an operational sales decline of 1.0% as compared to the prior year fiscal third quarter. The
Advanced Surgery operational decline was primarily driven by China volume-based procurement, the impact of the surgery
transformation program and disruptions in the Middle East across all platforms as well as competitive pressures in Endocutters and
Energy. This was partially offset by the strength of the portfolio and commercial execution in Biosurgery and new product launches
in Energy and Endocutters. The operational decline in General Surgery was primarily driven by China volume-based procurement
partially offset by technology penetration and upgrades within the differentiated Wound Closure portfolio coupled with market
expansion.
The Vision franchise achieved operational sales growth of 5.1% as compared to the prior year fiscal third quarter. The Contact
Lenses/Other operational growth was driven by strong performance in the ACUVUE OASYS 1-Day family of products including
recent launches and strategic price actions partially offset by inventory dynamics. The Surgical operational growth was primarily
driven by the strength of recent product innovations, robust demand for premium IOLs and strong commercial execution partially
offset by disruptions in the Middle East.
The Orthopaedics franchise achieved operational sales growth of 3.4% as compared to the prior year fiscal third quarter. The
operational growth in Hips was due to new product launches. The operational growth in Knees was driven by the strength of the
ATTUNE portfolio driven in part by pull through related to the VELYS Robotic assisted solutions. The operational growth in Trauma
was primarily driven by recently launched products and commercial execution partially offset by inventory dynamics outside the
U.S. The operational growth in Spine, Sports & Other was driven by new product innovations partially offset by competitive
pressures and inventory dynamics.
In October 2025, the Company announced its intention to separate its Orthopaedics business and expects the separation to be
completed in mid-2027.
Table of Contents
Form 10-Q 43

-- 48 of 61 --

Analysis of consolidated earnings before provision for taxes on income
Consolidated earnings before provision for taxes on income for the fiscal nine months of 2026 was $12.8 billion representing 17.1%
of sales as compared to $27.6 billion in the fiscal nine months of 2025, representing 39.7% of sales. Consolidated earnings before
provision for taxes on income for the fiscal third quarter of 2026 was $34.0 million representing 0.1% of sales as compared to $7.5
billion in the fiscal third quarter of 2025, representing 31.2% of sales. The fiscal third quarter and nine months of 2026 includes a
charge of approximately $5.5 billion related to the proposed talc ovarian litigation resolution and $1.0 billion of acquired in-process
research and development expense related to the acquisition of Firefly Bio, Inc. The fiscal nine months of 2025 includes
approximately $7.0 billion related to the talc reserve reversal.
Cost of products sold
$24.3 $22.3
32.4% 	32.0%
Q3 YTD 2026 Q3 YTD 2025
$8.1 	$7.3
31.9% 	30.4%
Q3 2026 	Q3 2025
(Dollars in billions. Percentages in chart are as a percent to total sales)
Fiscal nine months Q3 2026 versus Fiscal nine months Q3 2025
Cost of products sold increased slightly as a percent to sales driven by:
• Unfavorable product mix primarily driven by the decline of STELARA sales in the Innovative Medicine business
• Increased intangible asset amortization expense in the Innovative Medicine segment for Intra-Cellular (additional CAPLYTA
indication)
partially offset by
• Impact of tariff recoveries of approximately $0.2 billion in the MedTech business
• Favorable currency in the Innovative Medicine business
The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2026 and 2025 was
$3.7 billion and $3.4 billion, respectively.
Q3 2026 versus Q3 2025
Cost of products sold increased as a percent to sales primarily driven by:
• Unfavorable product mix primarily driven by the decline of STELARA sales in the Innovative Medicine business
• Increased intangible asset amortization expense in the Innovative Medicine segment for Intra-Cellular (additional CAPLYTA
indication)
partially offset by
• Impact of tariff recoveries of approximately $0.2 billion in the MedTech business
The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2026 and 2025 was
$1.2 billion and $1.0 billion, respectively.
Table of Contents
44

-- 49 of 61 --

Selling, marketing and administrative expenses
$18.8 $16.9
25.1% 	24.3%
Q3 YTD 2026 Q3 YTD 2025
$6.3 	$5.9
24.7% 	24.7%
Q3 2026 	Q3 2025
(Dollars in billions. Percentages in chart are as a percent to total sales)
Fiscal nine months Q3 2026 versus Fiscal nine months Q3 2025
Selling, Marketing and Administrative Expenses increased as a percent to sales primarily driven by:
• Commercial investments in the Innovative Medicine and MedTech businesses
Q3 2026 versus Q3 2025
Selling, Marketing and Administrative Expenses was flat as a percent to sales.
Research and development expense
Research and development expense by segment of business was as follows:
Fiscal Third Quarter Ended Fiscal Nine Months Ended
2026 2025 2026 2025
(Dollars in Millions) Amount % of Sales* Amount % of Sales* Amount % of Sales* Amount % of Sales*
Innovative Medicine $3,888 23.2% $2,944 18.9% $9,576 19.7% $8,361 18.7%
MedTech 764 8.8 728 8.6 2,256 8.6 2,052 8.2
Total research and
development expense $4,652 18.3% $3,672 15.3% $11,832 15.8% $10,413 15.0%
Percent increase over the prior
year
26.7% 13.6%
*As a percent to segment sales
Fiscal nine months Q3 2026 versus Fiscal nine months Q3 2025 and Q3 2026 versus Q3 2025
Research and Development increased as a percent to sales primarily driven by:
• Acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly Bio, Inc.
(Firefly)
In-process research and development (IPR&D) impairments
In the fiscal nine months of 2026, the Company recorded a charge of approximately $0.4 billion primarily related to PreCardia, a
non-strategic asset acquired as part of the Abiomed acquisition in 2022.
Table of Contents
Form 10-Q 45

-- 50 of 61 --

Interest (income) expense
Interest (income) expense in the fiscal nine months of 2026 was net expense of $136 million as compared to net income of $62
million in the fiscal nine months of 2025. The increase in net expense was driven by a lower average cash balance earning a lower
rate of interest and a higher average debt balance. Interest (income) expense in the fiscal third quarter of 2026 was net expense of
$31 million and was relatively flat as compared to net expense of $18 million in the fiscal third quarter of 2025. The balance of cash,
cash equivalents and current marketable securities was $17.2 billion at the end of the fiscal third quarter of 2026 as compared to
$18.6 billion at the end of the fiscal third quarter of 2025. The Company’s debt position was $44.6 billion as of September 27,
2026, as compared to $45.8 billion the same period a year ago.
Other (income) expense, net*
Fiscal nine months Q3 2026 versus Fiscal nine months Q3 2025
Other (income) expense, net for the fiscal nine months of 2026 was an expense of $6.4 billion as compared to $7.7 billion of income
in the prior year primarily due to the following:
Fiscal Nine Months
(Dollars in Billions)(Income)/Expense September 27, 2026 September 28, 2025 Change
Litigation related(1) $ 6.1 (6.9) 13.0
Orthopaedics separation related 0.7 0.0 0.7
Employee benefit related (0.5) (0.4) (0.1)
Changes in the fair value/sale of securities (0.3) (0.3) —
Sail Biomedicines Option Premium 0.3 0.0 0.3
Restructuring related 0.2 0.1 0.1
Acquisition, Integration and Divestiture related 0.1 0.4 (0.3)
Other (0.2) (0.6) 0.4
Total Other (Income) Expense, Net $ 6.4 (7.7) 14.1
(1) The fiscal nine months of 2026 includes a charge of $5.5 billion related to the proposed talc ovarian litigation resolution. The fiscal nine months
of 2025 include approximately $7.0 billion related to the talc reserve reversal. For additional details related to talc refer to Note 11 to the
Consolidated Financial Statements.
Q3 2026 versus Q3 2025
Other (income) expense, net for the fiscal third quarter of 2026 reflected an expense of $5.8 billion as compared to $0.5 billion of
income in the prior year primarily due to the following:
Fiscal Third Quarter
(Dollars in Billions)(Income)/Expense September 27, 2026 September 28, 2025 Change
Litigation related(1) $ 5.5 0.0 5.5
Orthopaedics separation related 0.3 0.0 0.3
Sail Biomedicines Option Premium 0.3 0.0 0.3
Employee benefit related (0.2) (0.1) (0.1)
Changes in the fair value/sale of securities 0.0 (0.4) 0.4
Acquisition, Integration and Divestiture related 0.0 0.1 (0.1)
Other (0.1) (0.1) —
Total Other (Income) Expense, Net $ 5.8 (0.5) 6.3
(1) The fiscal third quarter of 2026 includes a charge related to the proposed talc ovarian litigation resolution. For additional details related to talc
refer to Note 11 to the Consolidated Financial Statements.
*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain
investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and
Table of Contents
46

-- 51 of 61 --

losses on divestitures and on sales of assets, certain transactional currency gains and losses, acquisition and divestiture-related costs, litigation
accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.
Segment income before tax
Income before tax by segment of business for the fiscal nine months were as follows:
Income Before Tax Segment Sales Percent of Segment Sales
(Dollars in Millions)
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Innovative Medicine $16,632 $17,208 $48,567 $44,638 34.2% 38.6%
MedTech 3,192 3,912 26,204 24,991 12.2 15.7
Segment total 19,824 21,120 74,771 69,629 26.5 30.3
(Income) Expenses not allocated to segments(1) 7,053 (6,495)
Earnings before provision for taxes on income $12,771 $27,615 $74,771 $69,629 17.1 % 39.7 %
(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The
fiscal nine months of 2026 includes a charge of $5.5 billion related to the proposed talc ovarian litigation resolution. The fiscal nine months of
2025 include approximately $7.0 billion related to the talc reserve reversal. For additional details related to talc refer to Note 11 to the
Consolidated Financial Statements.
Innovative Medicine segment
The Innovative Medicine segment income before tax as a percent of sales in the fiscal nine months of 2026 was 34.2% versus
38.6% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal nine months of
2026 as compared to the prior year was primarily driven by the following:
• Acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly in 2026
• Expense of $0.3 billion primarily related to the option premium associated with Sail Biomedicines (Sail) in 2026
• Restructuring related costs of $0.3 billion in 2026
• Higher intangible asset amortization expense of $0.3 billion in 2026 related to Intra-Cellular (additional CAPLYTA indication)
• Unfavorable product mix in Cost of products sold, primarily driven by the decline of STELARA sales
partially offset by
• Favorable currency in Cost of products sold
MedTech segment
The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2026 was 12.2% versus 15.7% for the
same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal nine months of 2026 was
primarily driven by the following:
• Orthopaedics separation related costs of $0.7 billion in 2026
• Unfavorable changes in the fair value of securities of $0.2 billion versus 2025
• In-process research and development impairment charges of $0.4 billion in 2026, primarily related to PreCardia, a non-strategic
asset acquired as part of the Abiomed acquisition in 2022
partially offset by
• Impact of tariff recoveries of approximately $0.2 billion included in Cost of products sold
Table of Contents
Form 10-Q 47

-- 52 of 61 --

Income before tax by segment of business for the fiscal third quarters were as follows:
Income Before Tax Segment Sales Percent of Segment Sales
(Dollars in Millions)
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
September
27, 2026
September
28, 2025
Innovative Medicine $5,066 $6,446 $16,757 $15,563 30.2% 41.4%
MedTech 776 1,287 8,642 8,430 9.0 15.3
Segment total 5,842 7,733 25,399 23,993 23.0 32.2
(Income)/ Expenses not allocated to segments(1) 5,808 240
Earnings before provision for taxes on income $34 $7,493 $25,399 $23,993 0.1% 31.2%
(1) Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The
fiscal third quarter of 2026 includes a charge of $5.5 billion related to the proposed talc ovarian litigation resolution. For additional details
related to talc refer to Note 11 to the Consolidated Financial Statements.
Innovative Medicine segment
The Innovative Medicine segment income before tax as a percent of sales in the fiscal third quarter of 2026 was 30.2% versus
41.4% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal third quarter of
2026 as compared to the prior year was primarily driven by the following:
• Acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly in 2026
• Expense of $0.3 billion primarily related to the option premium associated with Sail Biomedicines (Sail) in 2026
• Higher intangible asset amortization expense of $0.2 billion in 2026 related to Intra-Cellular (additional CAPLYTA indication)
• Favorable changes of $0.2 billion in the fair value of securities in 2025 as compared to 2026
• Restructuring related costs of $0.1 billion in 2026
• Unfavorable product mix in Cost of products sold, primarily driven by the decline of STELARA sales
partially offset by
• Favorable currency in Cost of products sold
MedTech segment
The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2026 was 9.0% versus 15.3% for the
same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal third quarter of 2026 as
compared to the prior year was primarily driven by the following:
• Orthopaedics separation related costs of $0.4 billion in 2026
• Unfavorable changes in the fair value of securities of $0.2 billion versus 2025
• In-process research and development impairment charge of $0.3 billion in 2026, related to PreCardia, a non-strategic asset
acquired as part of the Abiomed acquisition in 2022
partially offset by
• Impact of tariff recoveries of approximately $0.2 billion included in Cost of products sold
Restructuring
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative
Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program
is expected to be substantially complete by the end of 2029 with estimated costs between $0.7 billion and $0.8 billion, and include
site and supplier exit costs, decommissioning and asset impairments costs. The pre-tax restructuring expense was $74 million in the
fiscal third quarter of 2026, of which $103 million was recorded in Restructuring, a reversal of $18 million of expense in Cost of
products sold and a reversal of $11 million of expense in Other income and expense on the Consolidated Statement of Earnings
primarily related to exit costs. The pre-tax restructuring expense was $274 million in the fiscal nine months of 2026, of which $103
million was recorded in Restructuring and $171 million in Other income and expense on the Consolidated Statement of Earnings
primarily related to asset impairments and exit costs. Total project costs of approximately $0.3 billion have been recorded since
the restructuring was announced.
Table of Contents
48

-- 53 of 61 --

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and
focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The pre-tax
restructuring expense was $80 million in the fiscal third quarter of 2026, of which $44 million was recorded in Restructuring, $6
million in Cost of products sold and $30 million in Other income and expense on the Consolidated Statement of Earnings primarily
related to product exits. The pre-tax restructuring expense was $194 million in the fiscal nine months of 2026, of which $105
million was recorded in Restructuring, $30 million in Cost of products sold and $59 million in Other income and expense on the
Consolidated Statement of Earnings primarily related to product exits. The pre-tax restructuring expense was $128 million in the
fiscal third quarter of 2025, of which $35 million was recorded in Restructuring and $93 million in Other income and expense on the
Consolidated Statement of Earnings. The pre-tax restructuring expense was $157 million in the fiscal nine months of 2025, of which
$64 million was recorded in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings.
Total project costs of approximately $0.4 billion have been recorded since the restructuring was announced. This program will be
completed as of the fiscal fourth quarter of 2026 at a total project cost of approximately $0.6 billion.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to
streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring
expense was $41 million in the fiscal third quarter of 2026, of which $34 million was recorded in Restructuring and $7 million in
Cost of products sold on the Consolidated Statement of Earnings primarily for costs related to market and product exits. The pre-
tax restructuring expense was $65 million in the fiscal nine months of 2026, of which $39 million was recorded in Restructuring,
$1 million in Other (Income)/Expense and $25 million in Cost of products sold on the Consolidated Statement of Earnings primarily
for costs related to market and product exits. The pre-tax restructuring expense was $40 million in the fiscal third quarter of 2025,
of which $28 million was recorded in Restructuring and $12 million in Cost of products sold on the Consolidated Statement of
Earnings primarily for costs related to market and product exits. The pre-tax restructuring expense was $145 million in the fiscal
nine months of 2025, of which $80 million was recorded in Restructuring, $35 million in Cost of products sold and $30 million in
Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments as well as
market and product exits. Total project costs of approximately $0.9 billion have been recorded since the restructuring was
announced. This program will be completed as of the fiscal fourth quarter of 2026 at a total project cost of approximately $1.0
billion.
For further details related to the restructuring refer to Note 12 to the Consolidated Financial Statements.
Provision for taxes on income
The worldwide effective income tax rate for the fiscal nine months was 14.0% in 2026 and 21.5% in 2025.
For further details related to the fiscal 2026 provision for taxes refer to Note 5 to the Consolidated Financial Statements.
Table of Contents
Form 10-Q 49

-- 54 of 61 --

Liquidity and capital resources
Dividends to shareholders
$ (Billions)
9.6 	9.3
9 Months
YTD 2026
9 Months
YTD 2025
$ (Billions)
Acquisitions*, net of
cash acquired
1.3
14.8
9 Months
YTD 2026
9 Months
YTD 2025
*Includes business combinations and asset acquisitions
Cash flows
Cash and cash equivalents were $16.9 billion at the end of the fiscal third quarter of 2026 as compared with $19.7 billion at the end
of fiscal year 2025. The primary sources and uses of cash that contributed to the $2.8 billion decrease were:
(Dollars In Billions)
19.7 Q4 2025 Cash and cash equivalents balance
18.9 net cash generated from operating activities
(4.9) net cash used for investing activities
(16.8) net cash used for financing activities
$ 16.9 Q3 2026 Cash and cash equivalents
In addition, the Company had $0.3 billion in marketable securities at the end of the fiscal third quarter of 2026 and $0.4 billion at
the end of fiscal year 2025.
Cash flow from operations of $18.9 billion was the result of:
(Dollars In Billions)
$ 11.0 Net earnings
6.8 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and
asset write-downs partially offset by deferred tax provision and net gain on sale of assets/businesses
(2.9) an increase in accounts receivable and inventories
1.4 an increase in accounts payable and accrued liabilities
1.4 a decrease in other current and non-current assets
1.1 an increase in other current and non-current liabilities
0.1 rounding
$ 18.9 Net cash flows from operations
Table of Contents
50

-- 55 of 61 --

Cash flow used for investing activities of $4.9 billion was primarily from:
(Dollars In Billions)
$ (3.7) additions to property, plant and equipment
0.1 proceeds from the disposal of assets/businesses, net
(0.4) acquisitions, net of cash acquired
(1.0) acquired in-process research and development assets/related milestones
(0.5) net purchases of investments
0.9 credit support agreements activity, net
(0.3) Other and rounding
$ (4.9) Net cash used for investing activities
Cash flow used for financing activities of $16.8 billion was primarily from:
(Dollars In Billions)
$ (9.6) dividends to shareholders
(6.0) repurchase of common stock
(2.9) net repayment of short and long term debt
2.3 proceeds from stock options exercised/employee withholding tax on stock awards, net
(0.6) Other, primarily Auris shareholder payment (described in Note 11), Credit support agreements and rounding
$ (16.8) Net cash used for financing activities
The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion
in Commercial Paper. Furthermore, in June 2026, the Company secured a new 364-day Credit Facility of $12.5 billion (expiration on
June 23, 2027) which may be used for general corporate purposes including to support commercial paper borrowings. Interest
charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference
Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.
As of September 27, 2026, the Company had cash, cash equivalents and marketable securities of approximately $17.2 billion and
had approximately $44.6 billion of notes payable and long-term debt for a net debt position of $27.4 billion as compared to the
prior year fiscal third quarter net debt position of $27.2 billion. The Company anticipates that operating cash flows, the ability to
raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper
markets will continue to provide sufficient resources to fund operating needs, including the Company’s remaining balance of
approximately $9.0 billion related to talc matters, $3.2 billion related to the current portion of Corporate bonds due and
approximately $2.6 billion for the option to acquire Sail (refer to Note 10 to the Consolidated Financial Statements for further
details) and the remaining approximately $0.9 billion related to opioid settlements. In addition, the Company monitors the global
capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.
Dividends
On July 15, 2026, the Board of Directors declared a regular cash dividend of $1.34 per share, payable on September 8, 2026, to
shareholders of record as of August 25, 2026.
On October 13, 2026, the Board of Directors declared a regular cash dividend of $1.34 per share, payable on December 8, 2026, to
shareholders of record as of November 24, 2026. The Company expects to continue the practice of paying regular quarterly
cash dividends.
Other information
New accounting pronouncements
Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.
Table of Contents
Form 10-Q 51

-- 56 of 61 --

Economic and market factors
The Company operates in certain countries where the economic conditions continue to present significant challenges. The
Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue
to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for
operations in Venezuela, Argentina, Turkey and Egypt as highly inflationary, as the prior three-year cumulative inflation rate
surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction
programs, productivity improvements and periodic price increases.
The long-term implications of regional conflicts on the Company are difficult to predict. The financial impact of known existing
conflicts, particularly in the Middle East, negatively impacted growth in the MedTech Surgery business in the fiscal third quarter of
2026.
Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing
existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information
to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A
change in statutory tax rate in any country would result in the revaluation of the Company’s deferred tax assets and liabilities
related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or
benefit recorded to the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they
arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or
benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.
The Company may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any
jurisdiction that favor domestic companies and technologies over foreign competitors.
The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care
cost containment and government legislation relating to sales, promotions and reimbursement of health care products including
recent actions in the U.S. and foreign countries such as Germany. Recent U.S. policy initiatives have focused on prescription drug
affordability, including the use of, international reference pricing methodologies, intended to reduce costs for American patients
and the U.S. Government. The Company has entered into voluntary agreements with the U.S. government that include patient
affordability initiatives, participation in certain pricing programs, and continued investment in U.S.-based research, development,
and manufacturing capabilities. The Company continues to implement and evaluate the potential effects of these agreements and
related policy initiatives.
Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical
procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance
coverage, may continue to impact the Company’s businesses.
The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers,
seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the
applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with
the FDA or otherwise challenged the coverage and/or validity of the Company’s patents. In the event the Company is not
successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue
may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and
which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors
could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid
patents are in place.
Item 3 — Quantitative and qualitative disclosures about
market risk
There has been no material change in the Company’s assessment of its sensitivity to market risk since its presentation set forth in
Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in its Annual Report on Form 10-K for the fiscal year ended
December 28, 2025.
Table of Contents
52

-- 57 of 61 --

Item 4 — Controls and procedures
Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of
the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated
and communicated to the Company’s management, including its principal executive and principal financial officers, or persons
performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive
Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and
participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period
covered by this report, the Company’s disclosure controls and procedures were effective.
Internal control. During the period covered by this report, there were no changes in the Company’s internal control over financial
reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial
reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls
and procedures.
The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems
for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to
support the growth of the Company’s financial shared service capabilities and standardize financial systems. This initiative is not in
response to any identified deficiency or weakness in the Company’s internal control over financial reporting. In response to this
initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.
Table of Contents
Form 10-Q 53

-- 58 of 61 --

Part II — Other information
Item 1 — Legal proceedings
The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements
(unaudited) — Notes to Consolidated Financial Statements.
Item 2 — Unregistered sales of equity securities and use
of proceeds
(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.
The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter
of 2026. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's
compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal
third quarter.
Fiscal Month Period
Total Number
of Shares
Purchased(1)
Avg. Price
Per Share
Total Number of
Shares
Purchased as
Part of Publicly
Announced Plans
or Programs
Maximum Number of
Shares that May Yet
Be Purchased Under
the Plans or Programs
June 29, 2026 through July 26, 2026 3,265,000 251.70 — —
July 27, 2026 through August 23, 2026 1,177,561 270.67 — —
August 24, 2026 through September 27, 2026 2,100,509 270.53 — —
Total 6,543,070 261.16 — —
(1) During the fiscal third quarter of 2026, the Company repurchased an aggregate of 6,543,070 shares of Johnson & Johnson Common Stock in
open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company’s compensation
programs.
Table of Contents
54

-- 59 of 61 --

Item 5 — Other information
Securities trading plans of Directors and Executive Officers. During the fiscal third quarter of 2026, none of our directors or
officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a “Rule 10b5-1 trading
arrangement” or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.
Item 6 — Exhibits
Exhibit 31.1 Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002 — Filed with this document.
Exhibit 31.2 Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002 — Filed with this document.
Exhibit 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with
this document.
Exhibit 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with
this document.
Exhibit 101:
EX-101.INS Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document
EX-101.SCH Inline XBRL Taxonomy Extension Schema
EX-101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase
EX-101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
EX-101.DEF Inline XBRL Taxonomy Extension Definition Document
Exhibit 104: Cover Page Interactive Data File––the cover page interactive data file does not appear in the
Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
Table of Contents
Form 10-Q 55

-- 60 of 61 --

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
Date: October 21, 2026
Date: October 21, 2026
JOHNSON & JOHNSON
(Registrant)
By /s/ J. J. Wolk
J. J. Wolk, Executive Vice President, Chief Financial
Officer (Principal Financial Officer)
By /s/ R. J. Decker Jr.
R. J. Decker Jr., Controller (Principal
Accounting Officer)
Table of Contents
56

-- 61 of 61 --